{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJ7f8JoIDA","lastupdate":"2023-12-27T00:00:00.000Z","update_date":"2023-12-27T00:00:00.000Z","lastModified":"Oct 21, 2025","active":1,"confidence_score":100,"confidence_score_reason":"markets","urlname":"alpha-tau-medical","minimal_profile":null,"status":"Public","fullstatus":"Public on NASDAQ on Mar, 2022;","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$netRzF6PJ9RqM0XYpCnTdyrbSmywONizZq2EzALdvgSgRXQEZGAOl1","name":"Alpha Tau Medical","oneliner":"Cancer Radiotherapy","registrar":"515344539","website":"https://www.alphatau.com/","careerspage":"https://www.alphatau.com/careers","founded_month":1,"founded_year":2016,"formernames":[],"sociallinks":{"twitter":"https://twitter.com/AlphaTauMedical","youtube":"https://www.youtube.com/channel/UCMmWvVwo1iEaQbncaIrK1PQ","facebook":"https://www.facebook.com/AlphaTauMedical","linkedin":"https://www.linkedin.com/company/10538741","instagram":""},"social":["https://www.linkedin.com/company/10538741","https://www.youtube.com/channel/UCMmWvVwo1iEaQbncaIrK1PQ","https://www.facebook.com/AlphaTauMedical","https://twitter.com/AlphaTauMedical"],"flattenedsociallinks":"https://www.linkedin.com/company/10538741|https://www.youtube.com/channel/UCMmWvVwo1iEaQbncaIrK1PQ|https://www.facebook.com/AlphaTauMedical|https://twitter.com/AlphaTauMedical","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"51-200","employees_exact":106,"patent":1,"raised":181900000,"stage":"Public","public_stage":"Public","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Alpha.Tau","Alpha-Tau","Alfa Tau","Alphatau","Alpha Tau"],"about":"Alpha Tau is a medical device company that focuses on the development and commercialization of its Diffusing Alpha-emitters Radiation Therapy (DaRT) for the treatment of solid cancers. \n\nThe technology, which was developed at Tel Aviv University in 2003, enables a highly potent and conformal radiotherapy treatment using alpha-emitting atoms. Directly inserted into the tumor, the Alpha DaRT seeds release a high-energy dose over a range of several millimeters, enabling a focal alpha-radiation treatment that spares the surrounding healthy tissue. \n\nIn 2017, Alpha Tau started with its first-in-human study of locally advanced and recurrent SCC cancers of the skin and head and neck, the results of which were subsequently published in the prestigious International Journal of Radiation Oncology | Biology | Physics. Following these initial encouraging results, Alpha Tau substantially expanded its clinical evaluations in later trials to a much wider patient population. \nThe supportive data from these first trials also led to the FDA granting Breakthrough Device Designation to the Alpha DaRT for the treatment of patients with SCC of the skin or oral cavity without curative standard of care. Later on, Alpha Tau also received FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM (glioblastoma multiforme). \n\nToday, in partnership with a number of esteemed medical and educational institutions worldwide, Alpha Tau has commenced several clinical and pre-clinical studies which are presently ongoing, and is also currently evaluating other potential uses of the Alpha DaRT technology for indications such as breast, pancreas, lung, GBM and prostate cancers, as well as other applications such as combinations with immunotherapies.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97236182477","country":null,"address":{"israeli":[{"id":"c3b074ad-eb56-4c81-a5b7-2e7989ecbf06","city":"Jerusalem","type":null,"address":"Kiryat HaMada Street 5, Jerusalem, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"c39c8e2b-9767-4263-8ce6-a651cdaf956c","city":"Lawrence","address":"1 Union St, Lawrence, MA, USA","country":"United States","placeid":null}]},"headquarter_address":null,"district":"Jerusalem District","news":[{"id":"cshHJi6Q9YiUIXcG6XG5CgLNzzVbPDhuxgEyYKViEnFeYgs8hmh48O","date":"Oct 21, 2025","link":"https://finance.yahoo.com/news/alpha-tau-announces-receipt-radioactive-123000972.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"manufacturing","round":null,"company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd. has achieved a significant milestone by securing a radioactive material license from the State of New Hampshire, marking a critical step towards the commercial-scale manufacturing of its innovative cancer therapy, Alpha DaRT®. The license allows the company to introduce radioactive material and continue preparations for manufacturing operations expected to begin in 2026. The facility, located in Hudson, New Hampshire, is being constructed in phases, with the first phase having a capacity of approximately 400,000 Alpha DaRT sources. This development is part of Alpha Taus broader strategy to commercialize its alpha-radiation cancer therapy, which is currently undergoing multiple clinical trials for various cancers.","partners":"A&M Construction","customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["license","manufacturing","facility","cancer","therapy"],"date_of_event":"October 21, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Expand","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage #Expand #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"MhehcTph8FIj8S94GBn5KTPisfRxWxjMKQBT9eufVE1bLdnjXXp1HE","news_summary":"Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"f4Qm6nhUGleyE3JtMdEJKQkGULBXHR4qe0kB6ZfHDfEespTxYXkwcB","date":"Sep 2, 2025","link":"https://finance.yahoo.com/news/alpha-tau-successfully-treats-first-123000643.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"cancer therapy","round":null,"company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd. has initiated a multi-center pilot study in the U.S. for its Alpha DaRT therapy, combined with chemotherapy, targeting newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma. This study, part of Alpha Taus broader strategy, aims to address the high unmet needs of pancreatic cancer patients, 87% of whom are inoperable at diagnosis. The trial, conducted at the University Cancer Centers in Houston, explores the safety, feasibility, and efficacy of Alpha DaRT, which uses localized alpha radiation to potentially improve treatment outcomes. This marks a significant step in developing innovative cancer therapies.","partners":null,"customers":"University Cancer Centers","eventType":null,"investors":null,"confidence":10,"key_topics":["pancreatic cancer","Alpha DaRT","pilot study","chemotherapy","innovation"],"date_of_event":"September 2, 2025","product_stage":"pilot","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Customers"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"We4yj3WC9PWcgtc5FeMNFN0AMyqIfkRI1iBEhX6hjiLW2cduGF5Qov","news_summary":"Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9kqOnNNtZhpEuNEwnJbARRBDLp6BewCkFj1rxES52kittkOOlgtJYi","date":"Aug 27, 2025","link":"https://finance.yahoo.com/news/alpha-tau-participate-five-september-123000641.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"cancer therapy","round":null,"company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd., an Israeli oncology therapeutics company, announced that its CFO, Raphi Levy, will present at five investor conferences in September 2025. The company is developing Alpha DaRT, an innovative alpha-radiation cancer therapy designed to destroy solid tumors while sparing healthy tissue. The technology is currently in clinical trials, with key milestones expected in 2025 and 2026. The company aims to explore the platforms potential for local tumor control and its immuno-stimulatory activity. The participation in these conferences indicates a growth-positive outlook as the company seeks to engage with investors and highlight its progress.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["Alpha DaRT","clinical trials","investor conferences","radiotherapy","oncology"],"date_of_event":"August 27, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Investment"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"jOyIboiRmjcKtLdj8ZVsGvJGMejz8LP91Iuhk7oW2O6zH7lC04TPOX","news_summary":"Alpha Tau to Participate in Five September Investor Conferences","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"XkGjxR3xml4XpEO3u9Z7kZpp2V2XT4BVN45iI0sLiKclXFWVutPSvU","date":"Aug 11, 2025","link":"https://finance.yahoo.com/news/alpha-tau-announces-second-quarter-200200097.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":["FDA approval","clinical trials"],"round":null,"company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd. has received FDA approval for an IDE to conduct a U.S. pilot study using Alpha DaRT for treating recurrent glioblastoma multiforme. The company is actively engaged in multiple U.S. clinical trials, including those for pancreatic cancer and GBM, with plans to initiate patient treatments in 2025. Alpha Tau has secured $36.9 million through a strategic equity offering from Oramed and is preparing for commercial scale-up, with a new facility in New Hampshire expected to be operational by early 2026. The company holds a cash balance of $83.3 million, supporting its clinical and commercial endeavors.","partners":["Oramed"],"customers":null,"eventType":null,"investors":["Oramed"],"confidence":10,"key_topics":["FDA approval","clinical trials","investment","commercialization","partnership"],"date_of_event":"August 11, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$36.9 million","structured_issues":["Product Stage","Investment","Expand"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage #Investment #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"nqDRyc9SvauUEX0eAfxFWIatrGzfafnQxkNeHN57YepPxnNLmapnFf","news_summary":"Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"reLQEPTf7Z2KNLz3YjZNhmRgSbt0QHj1nqZ9otgvP5Ldtd6jLoGeXB","date":"May 28, 2025","link":"https://finance.yahoo.com/news/alpha-tau-present-jefferies-global-123000517.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"conference","round":null,"company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd., an Israeli oncology therapeutics company, announced that its CFO, Raphi Levy, will present at the Jefferies Global Healthcare Conference on June 5, 2025. The company is known for its innovative alpha-radiation cancer therapy, Alpha DaRT, which targets solid tumors. The presentation will take place in New York, and Mr. Levy will be available for one-on-one investor meetings. Alpha DaRT is designed to deliver highly potent alpha-irradiation to tumors while sparing healthy tissue. The technology was developed by professors from Tel Aviv University. This event is expected to positively impact the company by increasing its visibility among investors.","partners":null,"customers":null,"eventType":null,"investors":[],"confidence":10,"key_topics":["Alpha DaRT","cancer therapy","conference","presentation","investor meetings"],"date_of_event":"June 5, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"AORMLra9kRGS1imGKKu6IQCxtLnH9qPDjFQIkKYmtu6XTBB7HL2rvW","news_summary":"Alpha Tau to Present at Jefferies Global Healthcare Conference","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"5k7ko3X6E7LjHuN73uPtlcc5SSLkcLW0ALd8XMATgES5R0rvY785G1","date":"May 19, 2025","link":"https://finance.yahoo.com/news/alpha-tau-announces-first-quarter-200100158.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trials","round":"registered direct financing","company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd. has reported significant progress in its clinical trials and corporate activities. The company shared positive interim results from trials of its Alpha DaRT® therapy for pancreatic cancer and head and neck squamous cell carcinoma. The FDA approved an Investigational Device Exemption for a U.S. pilot study of Alpha DaRT in pancreatic cancer and glioblastoma multiforme. The company completed a $36.9 million financing round with Oramed Pharmaceuticals, which also led to a strategic marketing alliance. Orameds CEO, Nadav Kidron, joined Alpha Taus Board of Directors. The company achieved MDSAP certification for its Jerusalem facility, facilitating international regulatory compliance. These developments position Alpha Tau for continued growth and expansion in the oncology field.","partners":"Oramed Pharmaceuticals, Inc.","customers":null,"eventType":null,"investors":"Oramed Pharmaceuticals, Inc.","confidence":10,"key_topics":["FDA approval","clinical trials","investment","partnership","manufacturing"],"date_of_event":"May 19, 2025","product_stage":"clinical trial","investment_date":"April 2025","acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$36.9 million","structured_issues":["Product Stage","Investment","Management Changes","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage #Investment #Management Changes #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"5stV7v9I1smUyPSjUjls44B3nChn3unQOEvnXMahGyqy7s4OrnlXJp","news_summary":"Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"yAUm9YOgWHiRezgE0XjaSMl38jeoMYGaCSsz4jhUULSZ7ueHXqKvtC","date":"May 12, 2025","link":"https://finance.yahoo.com/news/alpha-tau-announces-appointment-nadav-200100545.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"management changes","round":null,"company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd., an Israeli oncology therapeutics company, announced the appointment of Nadav Kidron, President, CEO, and Chairman of Oramed Pharmaceuticals Inc., to its Board of Directors. This appointment follows a strategic investment by an affiliate of Oramed. Alpha Tau is focused on the research, development, and potential commercialization of its innovative alpha-radiation cancer therapy, Alpha DaRT, designed for the treatment of solid tumors. The company views Mr. Kidrons extensive experience in leading public companies and his insights as valuable assets in advancing towards commercialization. Alpha DaRT technology aims to deliver highly potent alpha-irradiation to solid tumors while sparing healthy tissue.","partners":"Oramed Pharmaceuticals Inc.","customers":null,"eventType":null,"investors":"Oramed Pharmaceuticals Inc.","confidence":9,"key_topics":["Board appointment","Oncology therapeutics","Alpha DaRT","Strategic investment","Commercialization"],"date_of_event":"May 12, 2025","product_stage":"R&D","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes","Investment"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Management Changes #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"rcQjf0dCDqYAAiZIBOEW6dvXp5HACSkfNZL2pvMSCrRdc49749nXVk","news_summary":"Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"MiGXSvdcOqEGBPV84nr1y6H3LLKV3N3ihqG3RiyM4OYWwXJwukEeHz","date":"May 9, 2025","link":"https://finance.yahoo.com/m/01aec5db-7b5d-335d-afd3-b861eb8142cc/wex%2C-acelyrin%2C-and-more.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"activist investors","round":null,"company":"Acelyrin","layoffs":null,"summary":"The article discusses the involvement of activist investors with companies such as WEX and Acelyrin. These companies have seen action from these investors, as indicated by 13D filings with the Securities and Exchange Commission. A 13D filing is required when an entity acquires more than 5% of a companys securities, suggesting significant investor interest or potential influence over company decisions. The article highlights the potential impact of such investor actions on the companies involved, which could be growth-negative due to the pressure and changes activist investors might push for.","partners":null,"customers":null,"eventType":null,"investors":[],"confidence":9,"key_topics":["activist investors","stock action","13D filings","securities","disclosures"],"date_of_event":"May 9, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"YqikWgM28XlutG0GFqdR02rIYmvYxWM1CbuesU6NKJADs2HfnvPyS9","news_summary":"WEX, Acelyrin, and More Stocks See Action From Activist Investors","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"NXF67OBBBKf6JzhA5OBWitbcighT3C3vBeJfq7dMNeVeRfPNHqxpNh","date":"May 8, 2025","link":"https://finance.yahoo.com/news/alpha-tau-medical-2-other-180512494.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","round":null,"company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on developing its innovative Alpha DaRT technology for treating solid cancer. The company recently received FDA approval to initiate a pilot study for recurrent glioblastoma. Despite being pre-revenue and unprofitable, Alpha Tau maintains financial stability with sufficient cash runway for over two years. A recent follow-on equity offering raised $36.86 million, which could bolster development efforts but also poses a risk of share dilution. The seasoned management team is navigating the challenges of advancing clinical trials and product development.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["FDA approval","clinical trials","investment","oncology","financial health"],"date_of_event":null,"product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":"$182.29 million","impact_on_company":"growth-positive","investment_amount":"$36.86 million","structured_issues":["Product Stage","Investment","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage #Investment #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"0PBxjom1fpsYQeE6ti99j5Ni6FW19YZep8q0eRtKFADfFzZzRhvOan","news_summary":"Alpha Tau Medical And 2 Other Penny Stocks Worth Your Attention","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"VzEssPbIXA18oyK6mN6WN3pyozfELOr5WlybHgUIJpKxCUv0hl17mo","date":"May 6, 2025","link":"https://finance.yahoo.com/news/alpha-tau-participate-may-investor-123000135.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"investor relations","round":null,"company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd., an Israeli oncology therapeutics company, announced its participation in upcoming investor conferences in May 2025. The company, known for its innovative alpha-radiation cancer therapy, Alpha DaRT, will have its CFO, Raphi Levy, present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference and the Lytham Partners Spring 2025 Investor Conference. These events will provide opportunities for one-on-one investor meetings, highlighting the companys focus on research, development, and potential commercialization of Alpha DaRT for treating solid tumors. Alpha DaRT is designed to deliver potent alpha-irradiation to solid tumors while sparing healthy tissue.","partners":["H.C. Wainwright","Lytham Partners"],"customers":null,"eventType":null,"investors":[],"confidence":10,"key_topics":["Alpha DaRT","investor conferences","oncology","radiation therapy","solid tumors"],"date_of_event":"May 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ykbNcglE1YnZNvDWY4mHpaHoGHz8QsEfnMMjjHx44xxSVuplb2tNoe","news_summary":"Alpha Tau to Participate in May Investor Conferences","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"JvVf13KoYFOEuHYAZI134XJ4AJxiDN6J8IwgBJzCIklPY98V0S2Tis","date":"Apr 28, 2025","link":"https://finance.yahoo.com/news/oramed-pharmaceuticals-announces-36-9-130000565.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"partnership","round":null,"company":"Oramed Pharmaceuticals Inc.","layoffs":null,"summary":"Oramed Pharmaceuticals Inc. has made a strategic investment in Alpha Tau Medical Ltd., acquiring approximately 14.1 million shares at $2.612 per share through a registered direct offering. This partnership aims to leverage Orameds expertise in capital markets to support Alpha Taus innovative cancer therapy technology, Alpha DaRT®. The collaboration includes a three-year service agreement where Oramed will provide strategic guidance and appoint two directors to Alpha Taus Board. This alliance is expected to accelerate Alpha Taus clinical trials, manufacturing scale-up, and commercialization efforts, aligning with Orameds growth strategy in therapeutic delivery technologies.","partners":"Alpha Tau Medical Ltd.","customers":null,"eventType":"PIPE","investors":"Oramed Pharmaceuticals Inc.","confidence":9,"key_topics":["strategic investment","cancer therapy","partnership","clinical trials","commercialization"],"date_of_event":null,"product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Partners #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"bHaELrUmAneYm1kd3iJXGcyPLupqspCqMUe1wGOX7TpVHeNu27gJha","news_summary":"Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"JBy3EvdzCzzlIKUfHbRNlT0LDTGHJmbGladSGCw9xHUvmnLj61W6NW","date":"Apr 28, 2025","link":"https://www.prnewswire.com/il/news-releases/oramed-pharmaceuticals-announces-36-9-million-investment-and-strategic-collaboration-with-alpha-tau-medical-302439636.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"strategic investment","round":null,"company":"Oramed Pharmaceuticals Inc.","layoffs":null,"summary":"Oramed Pharmaceuticals Inc. has made a strategic investment in Alpha Tau Medical Ltd., acquiring approximately 14.1 million shares at $2.612 per share through a registered direct offering. This partnership aims to leverage Orameds expertise in capital markets to support Alpha Taus innovative cancer therapy technology, Alpha DaRT®. The collaboration includes a three-year service agreement where Oramed will provide strategic guidance and appoint two directors to Alpha Taus board. This alliance is expected to accelerate Alpha Taus clinical trials and commercialization efforts, particularly in the U.S., while expanding manufacturing capabilities. Both companies share a vision of revolutionizing therapeutic delivery, with Oramed focusing on oral drug delivery and Alpha Tau on precision radiation therapy.","partners":["Alpha Tau Medical Ltd."],"customers":null,"eventType":"PIPE","investors":"Oramed Pharmaceuticals Inc.","confidence":9,"key_topics":["strategic investment","cancer therapy","partnership","clinical trials","commercialization"],"date_of_event":null,"product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Partners #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"0x5rMR9h9TNsBLwyOZzZWMhWDiJxAM0GsvJHxaEamGJquXNT9QdFYs","news_summary":"/PRNewswire/ -- Oramed Pharmaceuticals Inc. (\"Oramed\" or the \"Company\"), (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"GDarZxGwVGkvKZvBx1OAQO9EEkdmBuu0zaLbBI5nXPZmH5df7ReKl3","date":"Apr 28, 2025","link":"https://finance.yahoo.com/news/alpha-tau-announces-closing-36-130000537.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"investment","round":null,"company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd. has successfully closed a registered direct offering, raising approximately $36.9 million from an affiliate of Oramed Pharmaceuticals Inc. This investment will support Alpha Taus growth, including expansion into multiple internal organ applications, scaling up manufacturing capabilities, and commercial preparations. The partnership with Oramed will also provide strategic services such as investor and public relations. Alpha Tau is currently conducting four active U.S. trials and is expanding its clinical and commercial roadmap. The offering was made under a registration statement filed with the SEC.","partners":"Oramed Pharmaceuticals Inc.","customers":null,"eventType":"PIPE","investors":"Oramed Pharmaceuticals Inc.","confidence":10,"key_topics":["investment","partnership","clinical trials","manufacturing","commercialization"],"date_of_event":"April 28, 2025","product_stage":"clinical trial","investment_date":"April 28, 2025","acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$36.9 million","structured_issues":["PIPE/PO","Partners","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#PIPE/PO #Partners #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"RRyBokT5mZD2lWuvbAPHcjuvUfNALeSvauswlKOtCWUgetE9s89m8M","news_summary":"Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"UpUsTTa4nb3KMrKcKiJd2eXpmz7maYpSp8x4cDzT7kXp7x8ZpMdjak","date":"Apr 2, 2025","link":"https://finance.yahoo.com/news/alpha-tau-receives-fda-approval-123000260.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","round":null,"company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd. announced that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for their Alpha DaRT technology in treating recurrent glioblastoma. This approval is a significant milestone for the company, as it follows previous FDA recognitions, including the Breakthrough Device Designation and acceptance into the Total Product Life Cycle Advisory Program. The clinical trial aims to enroll up to ten U.S. patients and will focus on evaluating the feasibility and safety of the treatment. Alpha DaRT is designed to deliver potent alpha-irradiation to solid tumors, sparing healthy tissue. This development is a promising step forward for patients with glioblastoma, a highly aggressive and treatment-resistant form of brain cancer.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["FDA approval","glioblastoma","clinical trial","Alpha DaRT","brain cancer"],"date_of_event":"April 02, 2025","product_stage":"pilot","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"pZTLKufTUt1OpKwe2zNjUc8hamKRuO1A0KC4toBxekGSSKYvMBeORw","news_summary":"Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"IeyudniC7QCSRRM0bD4uKJmqZsYoMGaflVLhkhOTDjnzKehZ0zc5NF","date":"Mar 18, 2025","link":"https://finance.yahoo.com/news/q1-virtual-investor-summit-demand-193000244.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"healthcare","round":null,"company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"The article discusses the presentations from the Q1 Investor Summit, highlighting various microcap companies and their developments. Alpha Tau Medical Ltd. is noted for achieving a 100% complete response rate in its recent U.S. trial results for skin cancer, indicating significant progress in its clinical trials. Other companies mentioned include Giftify, Inc., which is reaching profitability, and Vox Royalty Corp., which has shown substantial cash flow growth. The event provides a platform for investors to explore opportunities and insights from these companies, emphasizing their growth potential and market strategies.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["healthcare","investment","growth","technology","market"],"date_of_event":"March 11, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"hhRlYdI1DTFOPaFlHNazSZ70yNxkAqYdUDF2Ar4o0NjCUhfALLkdth","news_summary":"Q1 Virtual Investor Summit: On-Demand Presentations Now Live","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"D6UPb7iNEKD1LCo5XxwgPcxn5dA82Lw6y9PZXc7QsE19TmJ4T7P2jS","date":"Mar 18, 2025","link":"https://finance.yahoo.com/news/sidoti-events-llcs-virtual-march-130000551.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"conference","round":null,"company":"Sidoti Events, LLC","layoffs":null,"summary":"Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, is hosting a two-day March Small-Cap Conference on March 19-20, 2025, in New York City. The conference aims to provide a platform for small and microcap companies to present to investors and engage in meaningful interactions. Sidoti Events benefits from Sidoti & Companys extensive experience in securities research and its connections with 2,500 institutional relationships across North America. The conference will feature presentations from various companies, offering opportunities for networking and corporate access. Sidotis focus on small and microcap companies, along with its Company Sponsored Research program, positions it as a key player in providing corporate access and investor conferences.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["conference","small-cap","investors","research","networking"],"date_of_event":"March 19-20, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"6XtsdCnJ4CVlO6I9yb92e3knVS0PxdceSgL7vZufKvtD3a4xA7ttPs","news_summary":"Sidoti Events, LLC's Virtual March Small-Cap Conference","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"wJnhNxMPeHA8NTOM2dsIiitl1sknSsZ5Maymu3LZ47TL0GOYyasLMA","date":"Mar 12, 2025","link":"https://finance.yahoo.com/news/alpha-tau-announces-full-2024-200200125.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":["Clinical Trials","FDA Approval"],"round":null,"company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd. reported positive interim results from trials using its Alpha DaRT technology for treating pancreatic cancer and head and neck squamous cell carcinoma. The company received FDA approval for an Investigational Device Exemption to conduct a U.S. pilot study, marking a significant step towards regulatory approval. The trials showed high disease control rates and improved survival rates compared to historical data. Additionally, Alpha Tau was accepted into the FDAs Total Product Life Cycle Advisory Program to expedite market access for Alpha DaRT in treating glioblastoma multiforme. The company is expanding its operational capabilities with a new facility in Hudson, NH, and has a cash runway of at least two years.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["Alpha DaRT","Pancreatic Cancer","FDA Approval","Clinical Trials","Keytruda"],"date_of_event":"March 12, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Management Changes"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"zgMNCawAKTOE8Odx8iRdyizB5Nuu1gmZ51h3FDw4eHx6W30vRo0qs1","news_summary":"Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Ps9JtZZWJilIEdlKWHL5Bm9vwGeQuOTbsWrSh3mpvMgy1twDijFRr9","date":"Mar 3, 2025","link":"https://finance.yahoo.com/news/march-2025-penny-stocks-consider-170456976.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company focused on developing and commercializing Alpha DaRT for treating solid cancers in Israel and the United States. The company recently received FDA approval to expand its clinical trial for Alpha DaRT in pancreatic cancer patients, indicating potential growth opportunities. Despite being unprofitable and having increased losses over the past five years, Alpha Tau maintains a stable financial position with short-term assets exceeding liabilities and a cash runway for over two years. The management team is experienced, and shareholders have not faced significant dilution recently.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["oncology","clinical trial","FDA approval","financial health","growth prospects"],"date_of_event":null,"product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":"$211.71 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"dwic637fRcCmcoqEex2SP0aN7HoqGf3Ia5xicS3ue8gNUUM6FeV4qH","news_summary":"March 2025 Penny Stocks To Consider For Growth","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"DIPKTAtCKDeh0dYd5NcgCMGir23b0VOan7poN2lC5dWFdXxRqkQMOr","date":"Feb 27, 2025","link":"https://finance.yahoo.com/news/alpha-tau-participate-march-investor-140000581.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"investment","round":null,"company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd., an Israeli oncology therapeutics company, announced that its CFO, Raphi Levy, will present at several investor conferences in March 2025. The company is known for its innovative alpha-radiation cancer therapy, Alpha DaRT, which targets solid tumors. Alpha DaRT is designed to deliver potent alpha-irradiation directly to tumors, minimizing damage to surrounding healthy tissue. The technology was developed by professors from Tel Aviv University. The presentations at the Investor Summit, Oppenheimer Healthcare MedTech & Services Conference, and Sidoti Small Cap Conference aim to attract potential investors and partners. Alpha Taus participation in these events indicates a positive growth trajectory as it seeks to commercialize its promising cancer treatment technology.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["Alpha DaRT","Cancer therapy","Investor conferences","Radiation therapy","Solid tumors"],"date_of_event":"February 27, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"7UB9NzyRkh8SgENYYvCQqiHD7v4KdxGUJbHPAO3vxS8UKs7p7loSOl","news_summary":"Alpha Tau to Participate in March Investor Conferences","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9khKf2K7xgwhDHjBKuzk4oXgjvxGzl7ZDBFjspqTlO2UkFa62IOTAd","date":"Feb 24, 2025","link":"https://finance.yahoo.com/news/alpha-tau-receives-medical-device-133000007.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"certification","round":null,"company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd., an Israeli oncology therapeutics company, announced it has achieved Medical Device Single Audit Program (MDSAP) certification for its manufacturing facility in Jerusalem. This certification is a significant milestone for the company, as it underscores its commitment to quality, safety, and regulatory compliance. The MDSAP certification, which involves a streamlined auditing process across five international markets, is expected to expedite the commercialization of Alpha Taus innovative alpha-radiation cancer therapy, Alpha DaRT, for the treatment of solid tumors. The company is focused on expanding its manufacturing capabilities to meet the growing demand for its products in clinical trials, aiming to bring a game-changing product to market.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["MDSAP certification","Alpha DaRT","solid tumors","manufacturing","regulatory compliance"],"date_of_event":"February 24, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Expand"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9oe4ZZG6VVhO8x7Clju9IDmLEnJwGm9Zm5gqZ4eG6xLNPC7XoxNBNT","news_summary":"Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"qdKKVLswc8LMqxCohVWoWrVHqaiTQT5parScOG7yC1bM22rxaugSgk","date":"Feb 3, 2025","link":"https://finance.yahoo.com/news/alpha-tau-announces-fda-approval-133000917.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","round":null,"company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd. announced that it has received an FDA approval for an Investigational Device Exemption (IDE) supplement, allowing the expansion of its clinical trial for the Alpha DaRT cancer therapy. This approval enables the inclusion of a new cohort of locally advanced pancreatic cancer patients and increases the total number of patients to 30 across two cohorts. The trial will be conducted at up to 10 U.S. clinical trial sites. The IDE supplement is a significant step forward for Alpha Tau as it continues to explore new treatments for pancreatic cancer. Alpha DaRT is designed to deliver potent alpha-irradiation to solid tumors, aiming to destroy the tumor while sparing healthy tissue.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["FDA approval","clinical trial","cancer therapy","Alpha DaRT","pancreatic cancer"],"date_of_event":"February 3, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"4DknsE4NrtGR2mltIJPIkyXLAmt5osZLg37c25PRRlWdeuEjg66pCY","news_summary":"Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"u9v99Q95sBYZu2jMcyssM0PyH6KGPIRqB7U5jIfExzvr2ncZtSO6hR","date":"Jan 27, 2025","link":"https://finance.yahoo.com/news/alpha-tau-announces-cornerstone-interim-140000086.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trials","round":null,"company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd. has announced positive interim data from multiple clinical trials involving their innovative cancer therapy, Alpha DaRT®. The trials, which include studies on pancreatic cancer and a combination study with pembrolizumab for head and neck cancer, have shown promising results in terms of safety and efficacy. The company has received an Investigational Device Exemption from the FDA to conduct a U.S. pilot study and approval from Frances Ministry of Health for a multicenter trial. These developments suggest significant progress in the clinical validation of Alpha DaRT, potentially enhancing treatment options for cancer patients.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["pancreatic cancer","Alpha DaRT","clinical trials","safety results","FDA approval"],"date_of_event":"January 27, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"5WApHjGPtwCRTyGHdNIA7QuIoTbpg5wPxphn6RN3WVqkBZDV4w2Iuh","news_summary":"Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"IbYWazrsChAgd2HVN4vaDw6JfWpxGdIq2IbQOWw9QuNsgdfqHKMTqO","date":"Jan 8, 2025","link":"https://finance.yahoo.com/news/us-penny-stocks-consider-january-130910181.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"oncology, therapeutics","round":null,"company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company focused on developing its Alpha DaRT technology for treating solid cancers. Despite being pre-revenue and reporting net losses, the company maintains a strong cash position, ensuring operational continuity for over two years. Alpha Tau has been accepted into the FDAs Total Product Life Cycle Advisory Program, which could expedite market access for its therapies. Recent management changes include the appointment of Maya Netser, who brings valuable experience in technology leadership and commercialization. The companys market cap stands at $221.66 million.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["oncology","FDA","technology","investment","leadership"],"date_of_event":"January 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":"$221.66 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Management Changes"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"fTS8G0K31OLrfip460SenySMellOZxFd24LKnHGRNLPxYcshQVOqnn","news_summary":"US Penny Stocks To Consider In January 2025","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ghLfrqcxayGdXrKqTq5ho2v884NFle8KfCX02PAorUvYlP4gDPfawW","date":"Dec 18, 2024","link":"https://finance.yahoo.com/news/alpha-tau-announces-upcoming-presentation-133000275.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trials","company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd., an Israeli oncology therapeutics company, announced that its abstract on the feasibility, safety, and tumor control of a novel alpha-emitting radionuclide for pancreatic adenocarcinoma has been accepted for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium. The company will present its findings on January 24, 2025, and host an R&D Update Day on January 27, 2025, to review new data from its Canadian pancreatic cancer trial and other clinical trials. The company aims to showcase the potential of its Alpha DaRT technology in treating internal organ tumors and highlight its systemic benefits. This development marks a significant milestone for Alpha Tau, as it is the first time its data will be presented at an ASCO symposium.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["cancer therapy","clinical trials","ASCO symposium","pancreatic cancer","Alpha DaRT"],"date_of_event":"December 18, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"gvONIT3CzdWlzNv6PKBSJ0phdnrTWukFafxXVgDFLHOC0JiHh1HTl5","news_summary":"Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"bn5xZwf58bvARvZA1TRV6LM2glifWRNmijfGx4ab1Z7khQ5uEtnNkK","date":"Dec 17, 2024","link":"https://finance.yahoo.com/news/alpha-tau-announces-appointment-maya-140000573.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"management changes","company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd., a developer of alpha-radiation cancer therapy, announced the appointment of Ms. Maya Netser to its Board of Directors following its Annual General Meeting. Ms. Netser, with over 25 years of experience in technology leadership and advisory roles, is expected to contribute significantly to the companys strategic expansion into the treatment of internal organs. The outgoing board member, Mr. Meir Jakobsohn, will continue to serve in an advisory capacity. The company views this change as a positive step towards enhancing its mission to improve cancer care standards globally.","partners":[],"customers":[],"investors":[],"confidence":10,"key_topics":["Board Appointment","Cancer Therapy","Expansion","Leadership","Innovation"],"date_of_event":"December 17, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"L4zEw3CjskXXjZBdnfIHWYAygHFoHGUl3LazU2iy57MgTxsLMCu3fD","news_summary":"Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"oadfXK22pyQRKs1eiuFNWMoUWUF7pp0qZLu9heZelAQkko7Usu8HkH","date":"Dec 11, 2024","link":"https://finance.yahoo.com/news/alpha-tau-present-43rd-annual-133000271.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"conference","company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd., an Israeli oncology therapeutics company, announced that its CEO, Uzi Sofer, and CFO, Raphi Levy, will present a corporate overview at the J.P. Morgan 43rd Annual Healthcare Conference on January 16, 2025. The company, known for its innovative alpha-radiation cancer therapy, Alpha DaRT, will also host institutional investor meetings at the event. Alpha DaRT is designed to treat solid tumors with high-energy alpha particles, aiming to destroy tumors while sparing healthy tissue. The presentation will cover recent achievements and future data milestones. The event will be held at the Westin St. Francis in San Francisco, CA, and will be webcasted on the companys website.","partners":null,"customers":null,"investors":[],"confidence":10,"key_topics":["Alpha DaRT","oncology","presentation","conference","investors"],"date_of_event":"January 16, 2025","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"UXV9pzBnZpSEBRnhIsjPxI97mmB9iEfecCJxjCZ3uVJRlRcMCzTxyt","news_summary":"Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"nP6L076vkoRN98YDKMWOGzH3am90aCPHhpvwjQ0QOylemYqO6Vb0Kj","date":"Dec 6, 2024","link":"https://finance.yahoo.com/news/alpha-tau-participate-ladenburg-oncology-133000953.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"presentation","company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd., an Israeli oncology therapeutics company, announced that its CFO, Raphi Levy, will present at the Ladenburg Oncology Innovators & Investors Symposium on December 12, 2024. The company, known for its innovative alpha-radiation cancer therapy, Alpha DaRT, focuses on the research, development, and potential commercialization of treatments for solid tumors. The presentation aims to showcase the companys advancements and attract potential investors. Alpha DaRT technology, developed by Professors Itzhak Kelson and Yona Keisari, uses radium-224 to deliver targeted alpha-irradiation to tumors while sparing healthy tissue. The event will be held virtually, and interested parties can schedule one-on-one meetings with Mr. Levy through their Ladenburg representative.","partners":null,"customers":null,"investors":[],"confidence":10,"key_topics":["oncology","presentation","innovation","therapy","investment"],"date_of_event":"December 12, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HpS1hTSXcxapS991cOjIwxCKEDnswcBR4UVu4OqhJjrykfT6lTqPGj","news_summary":"Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"oMSSsoha8WKnaJltnv7MlszCMnc51QpYTqxkIJ8KPBMEYCdo5uJNsh","date":"Dec 2, 2024","link":"https://finance.yahoo.com/news/3-promising-penny-stocks-us-000946308.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"oncology, clinical trials","company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, is advancing its Alpha DaRT technology for treating solid cancers. Despite a net loss of US$22.27 million for the first nine months of 2024, the company has made significant regulatory progress. It was accepted into the FDAs Total Product Life Cycle Advisory Program to expedite market access for its treatment targeting recurrent glioblastoma multiforme. Additionally, it initiated clinical trials for lung cancer and received FDA approval to study recurrent cutaneous Squamous Cell Carcinoma in immunocompromised patients. These developments highlight potential growth avenues for the company.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["oncology","clinical trials","FDA approval","market access","financial health"],"date_of_event":"2024","valuation_amount":"$195.79M","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"My33SjsCymc8bGRx64En5AtOaWJuq9GOCmNMruccvjuugNSOV8B4go","news_summary":"3 Promising Penny Stocks In The US With Market Caps Under $400M","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"jBDaVp2vElJBzZfj1TAFWLmasXzX0nQCEetWQWHMFZ6Xw5w5NGwiXG","date":"Nov 19, 2024","link":"https://finance.yahoo.com/news/alpha-tau-medical-announces-third-210000476.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd. has been accepted into the FDAs Total Product Life Cycle Advisory Program (TAP) to expedite market access for its Alpha DaRT® therapy, aimed at treating recurrent glioblastoma multiforme. The company has also initiated a clinical trial in Israel for recurrent lung cancer, assessing the safety and feasibility of delivering Alpha DaRT® using an endobronchial ultrasound procedure. Additionally, the FDA has approved an Investigational Device Exemption (IDE) for a multi-center study on recurrent cutaneous squamous cell carcinoma in immunocompromised patients. Alpha Tau reported a cash balance of $68.4 million, providing a financial runway of at least two years. These developments highlight the companys progress in advancing its innovative cancer treatment technologies.","partners":["Hadassah Medical Center"],"customers":["patients with recurrent glioblastoma multiforme","patients with recurrent lung cancer"],"investors":null,"confidence":10,"key_topics":["FDA approval","clinical trials","cancer treatment","market access","financial results"],"date_of_event":"November 19, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"mZA77AGlO5rSiF6vOzkpFsq1wkqkjeF0hnyOFh6KyRo3ZQvCzopoAO","news_summary":"Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Jm8GZiqvB1RMaqd8gjb5Dc97nThavhDVa1BPFGEdFTt9jesaTkkftS","date":"Nov 13, 2024","link":"https://finance.yahoo.com/news/alpha-tau-participate-citi-2024-133000553.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"conference participation","company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd., an Israeli oncology therapeutics company, announced that its CFO, Raphi Levy, will participate in two major healthcare conferences in December 2024. The company, known for its innovative alpha-radiation cancer therapy, Alpha DaRT, will be represented at the Citi 2024 Global Healthcare Conference in Miami and the Piper Sandler 36th Annual Healthcare Conference in New York. These events provide opportunities for Alpha Tau to engage with potential investors and partners, showcasing their advancements in cancer treatment. The participation in these conferences is a positive step for the company, potentially enhancing its visibility and fostering growth.","partners":null,"customers":null,"investors":[],"confidence":10,"key_topics":["Alpha DaRT","conferences","oncology","Citi","Piper Sandler"],"date_of_event":"December 3, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"690yHs65IXcWc352Muy4b8aKMhGVkXv3jwkLNL8DPaAuV9mgcTzDdI","news_summary":"Alpha Tau to Participate in Citi’s 2024 Global Healthcare Conference and Piper Sandler’s 36th Annual Healthcare Conference","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"j1iLgFnhrGVNnKsNvf3bYrkWZQOQy8ZkS58gnXHCl9s8udyQh5ruSh","date":"Nov 1, 2024","link":"https://finance.yahoo.com/news/discover-alpha-tau-medical-2-170757750.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"oncology therapeutics","company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, is focused on developing and commercializing its Alpha DaRT technology for treating solid cancer. The company, with a market cap of $163.62 million, has been accepted into the FDAs TAP program, which aims to expedite market access for promising medical devices. Despite not generating significant revenue and facing increasing losses over the past five years, Alpha Tau maintains a strong financial position with more cash than debt. Recent clinical trials and FDA approvals indicate potential growth opportunities. The companys experienced management team provides strategic guidance, positioning it for future success in the oncology therapeutics market.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["oncology","FDA approval","clinical trials","financial health","growth potential"],"date_of_event":null,"valuation_amount":"$163.62M","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"m0ouKgqc0mCpVDXrX8BfdgJL6CuriMr6iZgqtDy5n9C9HZwX2H2S5p","news_summary":"Discover Alpha Tau Medical And 2 Other US Penny Stocks","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"r0f4kVDP8uJSMir2TjZEDlS45fjcJfuLQZH4ZROB3oF9hI84qMUZey","date":"Oct 21, 2024","link":"https://finance.yahoo.com/news/alpha-tau-announces-acceptance-fda-123000967.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd., an Israeli oncology therapeutics company, announced its acceptance into the FDAs Total Product Life Cycle (TPLC) Advisory Program Pilot. This program aims to expedite market access for their innovative cancer therapy, Alpha DaRT, specifically for treating recurrent glioblastoma multiforme (GBM). The acceptance follows the companys receipt of Breakthrough Device Designation from the FDA, highlighting the potential of Alpha DaRT to address unmet medical needs. The TPLC program will provide strategic guidance to accelerate the commercialization of Alpha DaRT, potentially benefiting the estimated 14,000 new GBM patients diagnosed annually in the U.S. Alpha Taus CEO, Uzi Sofer, expressed optimism about the programs impact on their GBM strategy and market presence.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["FDA approval","cancer therapy","glioblastoma","market access","innovation"],"date_of_event":"October 21, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"3w6FsKfdjw6HLoYxVMapFJ5E1ua8iVsdmDLkwOHxLEUuwOdQ9ARF4r","news_summary":"Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"gA5auqKz3Gugdk0g0xviuSdGejgxmhHEOhd96wWQcup09Dc6dr2SQ0","date":"Oct 11, 2024","link":"https://finance.yahoo.com/news/alpha-tau-alpha-dart-advances-125712037.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","company":"Alpha Tau Medical Ltd","layoffs":null,"summary":"Alpha Tau Medical Ltd has announced a significant milestone in its cancer treatment efforts by successfully treating its first patient with recurrent lung cancer using its innovative Alpha DaRT technology. This clinical trial, conducted at Hadassah Medical Center in Jerusalem, is designed to evaluate the safety, feasibility, and efficacy of the Alpha DaRT technology in treating tumors in the chest area. This advancement represents a promising development for patients with limited treatment options for lung cancer, which remains the leading cause of cancer-related deaths globally. The success of this trial could potentially enhance the companys reputation and growth prospects in the field of cancer therapy.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["cancer therapy","clinical trial","Alpha DaRT","lung cancer","treatment"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"T9TQRIly81b7xkvxrHK5MWCa5AK20gH24t3nfitRIaWG0btd9rdN5F","news_summary":"Alpha Tau’s Alpha DaRT Advances Lung Cancer Treatment","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"UbDRpbSU5BXCCYRr9ZFebcTbXoFwtf6aHU2AFlKMt5oSYSsNugMQBW","date":"Oct 10, 2024","link":"https://finance.yahoo.com/news/alpha-tau-treats-first-patient-123000546.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd. announced the treatment of its first patient with recurrent lung cancer using its innovative Alpha DaRT technology in a clinical trial at Hadassah Medical Center in Jerusalem. The trial aims to treat up to ten patients, assessing the safety and feasibility of delivering Alpha DaRT sources into the lung using an endobronchial ultrasound procedure. The study will also evaluate the efficacy of Alpha DaRT by examining tumor response. Lung cancer is a leading cause of cancer-related deaths worldwide, and this trial represents a significant advancement in treatment options. Alpha Taus CEO, Uzi Sofer, highlighted the importance of expanding Alpha DaRTs application to broader indications, particularly in complex cases like lung cancer.","partners":"Hadassah Medical Center","customers":null,"investors":null,"confidence":9,"key_topics":["Alpha DaRT","lung cancer","clinical trial","radiation therapy","Hadassah Medical Center"],"date_of_event":"October 10, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"GnYsnT7plR0DjBNLICXwQuaxBuS3z5IxsjM1f2Zago87dFKjAEPL3Y","news_summary":"Alpha Tau Treats First Patient with Recurrent Lung Cancer","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"cVmW54KVmWaLBFpNL8oM0PFgmZST3D9COAJQNhMgwdUujRVDutUgdQ","date":"Sep 23, 2024","link":"https://www.medicaldevice-network.com/news/fda-alpha-tau-cscc/","source":"www.medicaldevice-network.com","visible":1,"analysis":{"tags":"FDA approval","company":"Alpha Tau Medical","layoffs":null,"summary":"Alpha Tau Medical has received FDA approval for its investigational device exemption (IDE) application to initiate a study of its Alpha diffusing alpha-emitters radiation therapy (DaRT) for treating recurrent cutaneous squamous cell carcinoma (cSCC) in immunocompromised patients. The trial, led by the Winship Cancer Institute of Emory University, aims to enroll up to 28 subjects across eight institutions in the US. The study will measure the objective response rate (ORR) as its primary efficacy objective, with secondary objectives focusing on progression-free survival, overall survival, and local control up to 12 months post-treatment. The safety objective will monitor related adverse events.","partners":["Emory University"],"customers":[],"investors":[],"confidence":10,"key_topics":["FDA approval","clinical trial","Alpha DaRT","cSCC treatment","Emory University"],"date_of_event":"September 23, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"TuuvC4f3tR9FAgYyoPVv5V3TrGXxrk1cecEgXs3Dbd0tt1o5kNPcSC","news_summary":"FDA approves study of Alpha Tau’s Alpha DaRT for recurrent cSCC treatment","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"L5oTAvTd0Z5ekM7c7K4Hv7n0qUzv8tDqlpoBMNrpwzK5bfCUaXxDa0","date":"Sep 20, 2024","link":"https://finance.yahoo.com/news/alpha-tau-announces-fda-approval-123000441.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd. announced that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a multi-center study for treating recurrent cutaneous Squamous Cell Carcinoma (cSCC) in immunocompromised patients using its Alpha DaRT technology. The study, led by the Winship Cancer Institute of Emory University, will enroll up to 28 patients across 8 U.S. institutions. The primary objective is to measure the objective response rate, with secondary objectives including progression-free survival and overall survival. This trial aims to address a vulnerable patient population with limited treatment options.","partners":["Emory University"],"customers":["immunocompromised patients"],"investors":[],"confidence":10,"key_topics":["FDA approval","clinical trial","immunocompromised patients","Alpha DaRT","cSCC"],"date_of_event":"2024-09-20","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"oJmgTW3Djzy8kFOOv6I5prKvnyzVaDI6Wj0c85PtzQJm9caU6v91QY","news_summary":"Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"k4xDWrinK8GWhN87PJbfAOZHtTHDaKq48Tgdc6iGACOO3uOayNtD3A","date":"Sep 17, 2024","link":"https://finance.yahoo.com/news/sidoti-events-llcs-virtual-september-120000773.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"conference","company":"Sidoti & Company, LLC","layoffs":null,"summary":"Sidoti & Company, LLC, through its affiliate Sidoti Events, LLC, has announced the schedule for its September Small-Cap Conference, set to take place on September 18-19, 2024. Sidoti Events focuses on organizing investor conferences, leveraging Sidotis extensive experience in independent securities research. The conference will feature presentations from small and microcap companies, providing a platform for interaction between issuers and investors. Sidotis coverage includes approximately 150 equities, with a significant portion participating in its Company Sponsored Research program. The event aims to facilitate meaningful engagement for companies and investors in the small and microcap sector.","partners":[],"customers":[],"investors":[],"confidence":10,"key_topics":["conference","small-cap","research","investors","equities"],"date_of_event":"September 18-19, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"wugAuJqklYYRtHTfGX0DT7B1W07sCb3ZKK7TymqEp16VWa7FQ28pqV","news_summary":"Sidoti Events, LLC's Virtual September Small-Cap Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"IMIwALA4p6RLjTxuTQofjPdTMbIt5yfOikRY45C7lVywPtW8UXArWl","date":"Sep 3, 2024","link":"https://finance.yahoo.com/news/drts-company-seeks-develop-significant-124200599.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"cancer therapy","company":"Alpha Tau Medical","layoffs":"","summary":"Alpha Tau Medical, a therapeutics company, is developing Alpha DaRT, an innovative alpha-radiation cancer therapy designed to treat solid tumors with high precision while minimizing damage to surrounding healthy tissue. The company is advancing multiple clinical trials across various cancer types, including skin, pancreatic, lung, and brain cancers. Key milestones are expected between 2024 and 2025, including patient recruitment completion and initial data announcements. Alpha Tau has reported encouraging long-term safety and efficacy data and is scaling its manufacturing capabilities globally. With a strong cash position of $74.1 million, the company is well-positioned to continue its development efforts. However, it faces challenges in demonstrating clinical benefits over standard therapies and navigating regulatory pathways.","partners":[],"customers":[],"investors":[],"confidence":10,"key_topics":["Alpha DaRT","clinical trials","FDA approval","manufacturing","safety data"],"date_of_event":"2024-2025","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"","structured_issues":["Customers","Expand"],"acquisition_amount":"","structuredIssuesShow":"#Customers #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ZyBCngmeEyja3iN6jnf5udYuX4MKSv7kEX6jRYY5AvQdl6427Op4OS","news_summary":"DRTS: Company Seeks to Develop Significant Advance in Cancer Therapy with Alpha DaRT","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"yLKXFD6PqFiinO5ZaO8L10Hme7zdBqQPfvGXrkEFaVzZHwXUpU7Yki","date":"Aug 22, 2024","link":"https://finance.yahoo.com/news/alpha-tau-participate-h-c-123000399.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investment, Public Trading","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., an Israeli oncology therapeutics company, announced that its CFO, Raphi Levy, will present a corporate overview and update at several investment conferences in September and October 2024. These include the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference. Alpha Tau, founded in 2016, focuses on the research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors.","partners":"H.C. Wainwright, Sidoti, Rothschild & Co, Lytham Partners","customers":"Not mentioned","investors":"H.C. Wainwright, Sidoti, Rothschild & Co, Lytham Partners","confidence":9,"key_topics":["Investment Conference","Cancer Therapy","Alpha DaRT","Corporate Overview","Investor Relations"],"date_of_event":"August 22, 2024","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":["Investment","Public Trading"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment #Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"IUL648UYwIoC9BYFVAtJhZ1kxgw0nawmtRywB9Q2r312rxzrDpCgqE","news_summary":"Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ObLN3vQESgq91QLmD5gyctC4mDxACi7NWTBsNhnjOPdqz5RPCgcrZv","date":"Aug 14, 2024","link":"https://finance.yahoo.com/news/alpha-tau-medical-announces-second-200200820.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Cancer Therapy, Financial Results","company":"Alpha Tau Medical Ltd.","layoffs":"N/A","summary":"Alpha Tau Medical Ltd., an Israeli oncology therapeutics company, has reported its Q2 2024 financial results and provided a corporate update. The company has been developing its innovative alpha-radiation cancer therapy, Alpha DaRT®, and has seen positive results in its clinical trials. The company reported a cash balance of $74.1 million, which is expected to fund operations for at least two years. Alpha Tau is also preparing for potential future product launches and has secured approvals for a new manufacturing plant in Hudson, New Hampshire.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Cancer Treatment","Clinical Trials","Financial Results","Regulatory Approval","Product Launch"],"date_of_event":"August 14, 2024","valuation_amount":"N/A","impact_on_company":"Growth-Positive","investment_amount":"N/A","structured_issues":["Customers","Investment"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"IVcoayFE5VbAKf38pVWhaoot8FyqcBGbDTFP1qUvttCtCVqXBGsL9m","news_summary":"Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"S4Ypn7OBUelVhxE52j38l9EKazNJsH3qriQ3uuVHeIadvsBIsljSue","date":"Jun 25, 2024","link":"https://finance.yahoo.com/news/alpha-tau-announces-publication-cancers-123000841.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Cancer Treatment, Clinical Trials","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd. has published an article detailing the results of four international clinical trials of its alpha-radiation cancer therapy, Alpha DaRT. The trials showed an overall response rate of almost 100% in treated lesions and a complete response rate of 89%. No moderate or severe long-term toxicities were noted, and 2-year local recurrence-free survival was estimated at 77%. The companys CEO, Uzi Sofer, expressed optimism about the future of Alpha DaRT in treating hard-to-treat cancers. Further follow-up and additional clinical studies are ongoing.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":"Alpha DaRT, Cancer Treatment, Clinical Trials, Long-term Outcomes, Future Studies","date_of_event":"June 25, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment, Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"GMdaVawG4N8MVOiBcDmyokMYCgLF2eNPhtoWNAYBUZfRIDwELvejBh","news_summary":"Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"nClGQsEVpFoKX455lmscV77Vu7JDBFzscqjbljXwH5GgeZkNvMax3H","date":"May 21, 2024","link":"https://finance.yahoo.com/news/alpha-tau-present-jefferies-global-124500653.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Healthcare, Cancer Therapy","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"On May 21, 2024, Alpha Tau Medical Ltd., an Israeli medical device company specializing in alpha-radiation cancer therapy, announced that its CFO, Raphi Levy, will present a corporate overview and update at the Jefferies Global Healthcare Conference on June 5, 2024. The company, founded in 2016, is known for the development and potential commercialization of Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["CFO Presentation","Healthcare Conference","Investor Meetings","Cancer Therapy","Alpha DaRT"],"date_of_event":"May 21, 2024","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":"Management Changes","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"vx4P1X6fTaUKkAbuYBuUfqh5S556CVbZIyZikHqRoR23cBU1CPniIc","news_summary":"Alpha Tau to Present at the Jefferies Global Healthcare Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"LOqPgKRXBAWmhiANQvBQxwEzaInAvlqgHd3xuZYllzwavntKh3SBUn","date":"May 20, 2024","link":"https://finance.yahoo.com/news/alpha-tau-medical-announces-first-200100404.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Medical Research, Financial Results","company":"Alpha Tau Medical Ltd.","layoffs":"N/A","summary":"Alpha Tau Medical Ltd., a developer of alpha-radiation cancer therapy, has reported its first quarter 2024 financial results and provided a corporate update. The company has presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at the ESTRO 2024 Congress in Glasgow. It has also treated the first patient with liver metastases in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, Canada. The company reported a net loss of $8.0 million for the quarter ended March 31, 2024, compared to a net loss of $8.2 million for the same period in 2023. The company had cash and cash equivalents, deposits and restricted deposits in the amount of $80.7 million.","partners":"McGill University Health Center, Rambam Health Care Campus","customers":"Patients in various clinical trials","investors":"N/A","confidence":9,"key_topics":"Cancer Treatment, Clinical Trials, Financial Results, Research and Development, Expansion","date_of_event":"May 20, 2024","valuation_amount":"N/A","impact_on_company":"Growth-Positive","investment_amount":"N/A","structured_issues":"Investment, Customers, Expand","acquisition_amount":"N/A","structuredIssuesShow":"#Investment, Customers, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"erCTtNbBIaptw0JdsdSo1Zi8JKs452JNxt6Z1jpK1r0roSAJjcGJkV","news_summary":"Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Koaf1UcKyMxUeAUEXe9xRsfBakg4IKphXybyAmfD3bJF8LKrGbAmzl","date":"May 13, 2024","link":"https://finance.yahoo.com/news/alpha-tau-announces-alpha-dart-123000819.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Cancer Treatment, Clinical Trial","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd. has announced the treatment of its first patient with liver cancer metastases in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, Canada. The trial aims to recruit up to 10 patients for a two-staged hepatectomy to resect liver metastases of colorectal cancer. The study will examine the feasibility of delivering Alpha DaRT sources into the liver metastases and the safety of utilizing the Alpha DaRT sources in the liver. The trial is part of Alpha Taus strategy to showcase the broad use and potential of Alpha DaRT in treating other hard-to-treat indications.","partners":"McGill University Health Center","customers":"First patient with liver cancer metastases","investors":"Not mentioned","confidence":9,"key_topics":["Liver Cancer","Clinical Trial","Alpha DaRT","McGill University Health Center","Cancer Therapy"],"date_of_event":"May 13, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers","Partners"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"RGHaKfC6H7i8ZehEiiHaAKOEoWuSLxDt7twq4JFDd3Exu7maAqx1z8","news_summary":"Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d0SbYiAywall51S79HidbZkekG9gtXARtTYUvRAXpVvxrTLzZFDs1K","date":"May 6, 2024","link":"https://finance.yahoo.com/news/alpha-tau-presents-preclinical-data-123000381.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Cancer Treatment, Clinical Data","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd. has presented new preclinical data at the 2024 congress of the European Society for Radiotherapy and Oncology (ESTRO), showing significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT. The companys CEO, Uzi Sofer, stated that the results validate their plan to conduct future clinical trials examining the use of Alpha DaRT in combination with immunotherapy in patients with pancreatic cancer.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Cancer Therapy","Clinical Trials","Pancreatic Cancer","Alpha DaRT","Preclinical Data"],"date_of_event":"May 06, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment, Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"vrBjGRe7wySz4rPAnaCVRvlJPwZeChEOgNzC1L55pCQpkZF6I4jZGq","news_summary":"Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"QUyPAgfTdeGuPjlgtVKu0rpOLAQMieZFKnTwLlCbSiS1T8PErskc3S","date":"May 1, 2024","link":"https://finance.yahoo.com/news/alpha-tau-participate-may-investor-123000191.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investor Conference, Cancer Therapy","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, announced that its CFO, Raphi Levy, will present at two investor conferences in May 2024. The conferences include the Guggenheim Securities Radiopharmaceuticals Day and the H.C. Wainwright 2nd Annual BioConnect Investor Conference. Alpha Tau, founded in 2016, focuses on the research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Investor Conferences","CFO Presentation","Alpha DaRT","Cancer Therapy","Company Update"],"date_of_event":"May 01, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Management Changes","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"UWoAQg9sQSYLo0jopV1vjzbk5hkcqHKCkAdoW93HcxBjIjSma0E1Ut","news_summary":"Alpha Tau to Participate in May Investor Conferences","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"056OdtWInTMYTR6FTwCb3ruAvG0gOhv5Gton8ocrFx0bm54v9rR1CP","date":"Mar 25, 2024","link":"https://finance.yahoo.com/news/alpha-tau-present-jefferies-radiopharma-125000089.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Corporate Presentation, Innovation Summit","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, announced that its CFO, Raphi Levy, will present a corporate overview and update at the Jefferies Radiopharma Innovation Summit on April 11, 2024. The company, known for its innovative alpha-radiation cancer therapy Alpha DaRT, will also be available for one-on-one investor meetings at the conference.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Alpha DaRT","Cancer Therapy","Radiopharma Innovation Summit","Investor Meetings","Corporate Overview"],"date_of_event":"March 25, 2024","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":"Management Changes","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"YKQJTx10x9yiXNFg96gOyscAjS6TCgWVVUHlgJclDILt179XYQOYob","news_summary":"Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"pIU0YbmIJkEGAedZZEXCFd07q2HtSFfzTdAG7n6nIOYOlPXuoSfAxx","date":"Mar 7, 2024","link":"https://finance.yahoo.com/news/alpha-tau-medical-announces-full-210100375.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Cancer Treatment, Financial Results","company":"Alpha Tau Medical Ltd.","layoffs":"N/A","summary":"Alpha Tau Medical Ltd. has reported positive interim safety and feasibility data from a pancreatic cancer study in Montreal and has also submitted a PMDA application for recurrent Head and Neck cancer in Japan. The company has entered into a long-term lease for a second facility in the U.S. in Hudson, NH. Alpha Tau has a cash, deposits and restricted deposits balance of $84.9 million, which is expected to last for at least two years. The company is also planning to begin work on the construction of its second U.S. facility, in Hudson, NH, and on the construction plans for its second facility in Jerusalem.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Cancer Study","Financial Results","New Facilities","Clinical Trials","Regulatory Approval"],"date_of_event":"March 07, 2024","valuation_amount":"N/A","impact_on_company":"Growth-Positive","investment_amount":"N/A","structured_issues":["Investment","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Investment #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"tFfCyjlvA6HYGMsATViDcteAZgkTW4MR4YbRulFhQQkwvNOiuUd44l","news_summary":"Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"gcM1WnIowi0CQEPCxYHb0Ml6kC3D2lOxtEB0MJGjsE6xBn8yt5Sw0n","date":"Feb 26, 2024","link":"https://finance.yahoo.com/news/alpha-tau-participate-barclays-26th-133000734.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Healthcare Conference, Cancer Therapy","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, has announced that its management will participate in the Barclays 26th Annual Global Healthcare Conference on March 12th and 13th, 2024. The company, which was founded in 2016, focuses on the research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":"Healthcare Conference, Alpha DaRT, Cancer Therapy, Radium-224, Tumor Treatment","date_of_event":"Feb. 26, 2024","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":"Management Changes","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"zCmmknqZqbDvTfXuyf5mfzW6VmgczmLaIbaf4MkyQ8F1V9ZczV4g76","news_summary":"Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5uEkVhiJyldP0c7ABbLJP9iNZOXAMkPgdEECdcMtjmngHhVvApNuZp","date":"Feb 23, 2024","link":"https://finance.yahoo.com/news/alpha-tau-medical-nasdaq-drts-134629859.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Cash Burn, Financial Health","company":"Alpha Tau Medical","layoffs":"Not mentioned","summary":"Alpha Tau Medical, an unprofitable biotech company, is being analyzed for its cash burn rate. Despite not recording any revenue over the last year, the companys cash burn was $19m over the trailing twelve months, indicating a cash runway of 4.5 years from September 2023. The companys cash burn of $19m is about 9.1% of its $212m market capitalisation, suggesting it could raise more cash to fund growth with a little dilution, or even simply borrow some money. The companys cash runway and ability to raise more cash for growth are seen as positive signs.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":["Cash Burn","Financial Health","Cash Runway","Debt-free","Share Issuance"],"date_of_event":"Not specified","valuation_amount":"$212m market capitalisation","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HyZvjhqftUsqnzN5hK6RRSMnlJrO02DXQET0d8Yu9Bo6mjCI7NBKbF","news_summary":"Alpha Tau Medical (NASDAQ:DRTS) Is In A Good Position To Deliver On Growth Plans","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5LCzZ3d03ipEUwOUC5LadulEJ322ndwm2EnWqJMnrcTw3u4OIz0d23","date":"Jan 13, 2024","link":"https://finance.yahoo.com/news/alpha-tau-medical-ltd-nasdaq-134718652.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Ownership, Investment","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd.s ownership structure reveals that retail investors hold the majority stake in the company with 58% ownership, while insiders account for 22% of the companys stockholders. The largest shareholder is the CEO Uzi Sofer with 17% of shares outstanding, followed by Althera Medical Ltd. owning 15% of common stock, and Medison Ventures holding about 3.9% of the company stock. Institutional investors also have a significant stake in the company. The general public, mostly comprising of individual investors, collectively holds 58% of Alpha Tau Medical shares.","partners":"Not mentioned","customers":"Not mentioned","investors":["CEO Uzi Sofer","Althera Medical Ltd.","Medison Ventures"],"confidence":9,"key_topics":["Ownership Structure","Retail Investors","Institutional Ownership","Insider Ownership","Public Ownership"],"date_of_event":"Not mentioned","valuation_amount":"US$219m","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"PZ9SMmRWDofGcQiVFRhcRGBb6mbpiLkMOE7rYsiN7nqGo3mKlTZsp1","news_summary":"Alpha Tau Medical Ltd. (NASDAQ:DRTS) most popular amongst retail investors who own 58%, insiders hold 22%","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"bl3KkjM0LLcv7MmvIrzWnDLjJ1OYQwjrcJmfTQraIVXHo37UMQNVOE","date":"Dec 20, 2023","link":"https://finance.yahoo.com/news/alpha-tau-present-42nd-annual-141500364.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Healthcare, Cancer Treatment","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, announced plans to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. The company will review its recent achievements, including promising interim results from its pancreatic cancer safety and feasibility trial and robust long-term data from four clinical trials. The company will also be featured at the Biotech Showcase occurring in parallel, and will host institutional investor meetings at both conferences. Alpha Tau is the developer of the innovative alpha-radiation cancer therapy Alpha DaRT.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Cancer Therapy","Clinical Trials","Healthcare Conference","Investor Meetings","Alpha DaRT"],"date_of_event":"December 20, 2023","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":["Investment","Management Changes"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"tTYNFaUh2G0ufRR8zLiqTrgRQ4EOavwfKTzYNoZWbCdGzTcdR7Swc5","news_summary":"Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"rVMoeyihsjoOcKCqCCAGH01D3Q4OsmLRb1ctOLlGMYPBXJ9QNbbg29","date":"Dec 5, 2023","link":"https://finance.yahoo.com/news/sidoti-events-llcs-virtual-december-152500423.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Conference, Small-Cap","company":"Sidoti Events, LLC and Sidoti & Company, LLC","layoffs":"Not mentioned","summary":"Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has announced the schedule for its two-day December Small-Cap Conference taking place on December 6-7, 2023. The conference is part of Sidotis efforts to serve the needs of presenters and attendees more directly. Sidoti Events, LLC was formed in 2023 to focus on the companys growing conference business. The company benefits from Sidotis small- and microcap-focused nationwide sales force, which has connections with 1,500 institutional relationships in North America.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":"Small-Cap Conference, Corporate Access, Investor Relations","date_of_event":"December 5, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"VAlX5v09jUQEghfERhQl2uBaADyhdue6zR6SAlVL9E1yGGliI7XLce","news_summary":"Sidoti Events, LLC's Virtual December Small-Cap Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0vdJDgF9OhqXzonll3DqwIOM7Z6Wr0bdVvCW255DmxLk7NwYYAB0MX","date":"Nov 29, 2023","link":"https://finance.yahoo.com/news/alpha-tau-participate-sidoti-small-133000807.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Conference Presentation, Cancer Therapy","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, announced that its management will present at the Sidoti Small-Cap Virtual Conference on December 7th, 2023. The company, founded in 2016, focuses on the research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":"Alpha DaRT, Cancer Treatment, Conference Presentation, Medical Device, Research and Development","date_of_event":"Nov. 29, 2023","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":"Management Changes","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"y80po4xviaylOm5dChmNUNA4WcmB0t42TIPszEloOQCS5O55arkQ76","news_summary":"Alpha Tau to Participate in Sidoti Small-Cap Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"eysMaobvaOsDaOA9k2cNdaN3m7PEO02vsve9JAoGv5gEvxVWvwr6q1","date":"Nov 28, 2023","link":"https://finance.yahoo.com/news/alpha-tau-announces-highly-promising-133000923.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Medical Research, Cancer Treatment","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd. has released interim results from its safety and feasibility trial examining the use of Alpha DaRT to treat advanced pancreatic cancer. The first five patients were treated successfully with no serious adverse events related to the product. The trial is currently underway at two university hospitals in Montreal, Canada. The companys CEO, Uzi Sofer, expressed satisfaction with the initial results and looks forward to generating more data in 2024. The trial aims to recruit 37 participants with Stage II to IV pancreatic adenocarcinoma.","partners":"Jewish General Hospital, McGill University, Faculty of Medicine, Lady Davis Institute, MEDTEQ+, Institute TransMedTech","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Cancer Treatment","Clinical Trials","Medical Research","Alpha DaRT","Pancreatic Cancer"],"date_of_event":"Nov. 28, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"4RUY8m2dfWCfe2mvrMEBNXvNOg5cYJBKzDuCn4KNbwRWn3PuqAyJpY","news_summary":"Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"SnWgLVf4QcWP1zoC5zJ7deLhE7WQjRPseeMT90exHZbpnOzeCNeJUY","date":"Nov 19, 2023","link":"https://finance.yahoo.com/news/alpha-tau-submits-japanese-pmda-133000666.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Partnership, Medical Approval","company":"Alpha Tau Medical Ltd.","layoffs":"N/A","summary":"Alpha Tau Medical Ltd. and its partner HekaBio K.K. have announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has accepted Alpha Tau’s submission for pre-market approval of its alpha-radiation cancer therapy, Alpha DaRT, for patients with recurrent head and neck cancer. The submission is based on successful clinical trial results in Japan. Alpha Tau and HekaBio are also in discussions with several large biopharmaceutical companies about a potential long-term commercial partnership in Japan.","partners":"HekaBio K.K.","customers":"Patients with recurrent head and neck cancer","investors":"N/A","confidence":9,"key_topics":["Cancer Therapy","Clinical Trials","Regulatory Approval","Partnership","Market Expansion"],"date_of_event":"Nov. 20, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Partners","Customers"],"acquisition_amount":"N/A","structuredIssuesShow":"#Partners #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"UVJFSbx65Keqcn1X4fCvU3aoeRWcw52os686hhEhw1yiwLOMP47nkv","news_summary":"Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0bbMZWaj5bgBrA7L6gcjveptv3EiwL4E08Rm70U2jlLsYfQs7UL4qO","date":"Nov 16, 2023","link":"https://finance.yahoo.com/news/alpha-tau-medical-announces-third-213000260.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Results, Clinical Trials","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd. has reported its Q3 2023 financial results and provided a corporate update. The company has treated the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel and is conducting a safety and feasibility trial in Montreal, Canada. The company has appointed former U.S. FDA Commissioner, Stephen M. Hahn, M.D. to its Scientific Advisory Board. Alpha Tau has a cash, deposits & restricted deposits balance of $90.1 million, which is expected to last for at least two years. The company is also planning to increase its manufacturing capacity and has leased a second manufacturing site in the U.S.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Clinical Trials","Financial Results","Management Changes","Expansion","Investment"],"date_of_event":"Nov. 16, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Management Changes","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment #Management Changes #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"mb4pcqRJ2W4NUsC4noTnKMmb1ecM30hZ3muTCzsS60lukrKIpsrzNb","news_summary":"Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"hNlMq1qCy1O09cM6zI75Hi7G2Ysp19s1uFD8Slp0HZTagaqkzlTsr5","date":"Nov 1, 2023","link":"https://finance.yahoo.com/news/presenting-emerging-growth-conference-64-110000714.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Conference, Growth Sectors","company":"EmergingGrowth.com","layoffs":"N/A","summary":"EmergingGrowth.com, a leading independent small cap media portal, has announced the schedule for the 64th Emerging Growth Conference on November 1st and 2nd, 2023. The conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. The event will feature presentations from a variety of companies, including AGBA Group Holding Limited, Battery Mineral Resources Corp., Envoy Medical, Inc., and Houston Natural Resources Corp.","partners":"AGBA Group Holding Limited, Battery Mineral Resources Corp., Envoy Medical, Inc., Houston Natural Resources Corp.","customers":"N/A","investors":"N/A","confidence":8,"key_topics":["Emerging Growth Conference","Small Cap Media","Innovative Products & Services","Long-term Growth","Company Presentations"],"date_of_event":"November 1st and 2nd, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Customers, Partners","acquisition_amount":"N/A","structuredIssuesShow":"#Customers, Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"YkdqLPv1GO3nQva02Ve3UuB4Y8kk9agL5QRdkeIgBrzhaUt006XoF7","news_summary":"Presenting on the Emerging Growth Conference 64 Day 2 on November 2 Register Now","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"apr4c9VEtfMzNFhNHJnknQm79IDc24wxy8wzLSs6px4OLSr9uU2qwX","date":"Nov 1, 2023","link":"https://finance.yahoo.com/news/alpha-tau-participate-november-investor-123000852.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investor Conference, Cancer Therapy","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, announced that its management will participate in several investor conferences in November 2023. The company, which is known for its innovative alpha-radiation cancer therapy Alpha DaRT, will present at the Emerging Growth Conference, Jefferies London Healthcare Conference, and Piper Sandler 35th Annual Healthcare Conference. The presentations will include one-on-one meetings and a fireside chat.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Investor Conferences","Alpha DaRT","Cancer Therapy","Company Presentation","Healthcare Conference"],"date_of_event":"Nov. 01, 2023","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":"Public Trading","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"okvIppReTpvpMy9Pg15InKQlzuov4s5PUJI3elTWvcNU0Dlt9oPOff","news_summary":"Alpha Tau to Participate in November Investor Conferences","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5cyrRaazebUEbukmZ04OqLWkEaWjXVNwu6KR5EQkWj4xGnRIh3DKvi","date":"Oct 30, 2023","link":"https://finance.yahoo.com/news/alpha-tau-enters-long-term-123000511.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Expansion, Manufacturing","company":"Alpha Tau Medical Ltd.","layoffs":"N/A","summary":"Alpha Tau Medical Ltd. announced that its U.S. subsidiary, Alpha Tau Medical Inc., has entered into a long-term lease agreement for a standalone building in Hudson, New Hampshire. The company plans to erect its second U.S. manufacturing site at this location. The new site is expected to be larger than the existing one in Lawrence, Massachusetts, and will support the companys goals of scaling up capacity and achieving manufacturing redundancy. The company anticipates initiating manufacturing of Alpha DaRT treatments at this facility within two years.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Manufacturing Expansion","Lease Agreement","Alpha DaRT","Future Commercialization","Regulatory Approval"],"date_of_event":"Oct. 30, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"B8KWZHaQKX4VTY6GhabC0mS0pmXp9OG7ujjd1skvfIuHVv5zf7sQ0J","news_summary":"Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"aCndJsOldLGxMn08YwJ3WkhZFhtFrHX3ps32dAzyDiByIQRum7x4Zu","date":"Oct 24, 2023","link":"https://finance.yahoo.com/news/former-u-commissioner-food-drug-130000817.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Management Changes, Expansion","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, has announced that former FDA commissioner, Stephen M. Hahn, M.D., has joined its Scientific Advisory Board. The company, which is developing the innovative alpha-radiation cancer therapy Alpha DaRT, believes that Dr. Hahns regulatory and scientific experience will be invaluable as it seeks FDA clearance for its technology. The company is currently conducting clinical trials for the treatment of various types of cancer, including pancreatic, head and neck, and prostate cancers and glioblastoma.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["FDA Clearance","Cancer Therapy","Scientific Advisory Board","Clinical Trials","Alpha DaRT Technology"],"date_of_event":"Oct. 24, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Management Changes"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"rpxacQXtTO8AC7CKz3nDxX0bI4KMJ8frP1W7RaJsMRP0pToSoZVY4P","news_summary":"Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"xoSIwNhjQRyKOzBV4e0LbyQqzdn7T9LY3P0vNejLfKDy3MjDlFwRtv","date":"Oct 3, 2023","link":"https://finance.yahoo.com/news/presenting-emerging-growth-conference-63-110000441.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Conference, Growth Sectors","company":"EmergingGrowth.com","layoffs":"N/A","summary":"EmergingGrowth.com, a leading independent small cap media portal, has announced the schedule for the 63rd Emerging Growth Conference on October 4th and 5th, 2023. The conference identifies companies in a wide range of growth sectors, focusing on those with strong management teams, innovative products & services, and the potential for long-term growth. The event will feature presentations from a variety of companies, including AGBA Group Holding Limited, Loop Industries, Inc., CoTec Holdings Corp., and many more.","partners":"AGBA Group Holding Limited, Loop Industries, Inc., CoTec Holdings Corp., ASP Isotopes, Inc., Akari Therapeutics, plc, FendX Technologies, Inc., NeuroSense Therapeutics, Ltd., Coeptis Therapeutics Holdings, Inc., Rakovina Therapeutics Inc., Alpha Tau Medical, Inc., GeoVax Labs, Inc., Renforth Resources, Inc., NeuroMetrix, Inc., Theriva Biologics, Bioxytran, Inc., Inspire Veterinary Partners, Inc., BioLargo, Inc., Nextech3D.ai, Sokoman Minerals Corp., Knightscope, Inc., Cyngn, Inc., Citizens, Inc., Ampio Pharmaceuticals, Inc., Steppe Gold, Ltd., Regen Biopharma, Inc.","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Emerging Growth Conference","Small Cap Media","Growth Sectors","Company Presentations","Investment Community"],"date_of_event":"October 4th and 5th, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Customers, Partners","acquisition_amount":"N/A","structuredIssuesShow":"#Customers, Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"k8TiLe60u1PStwDlLjPxMN5iwWvKDjqVjXUyI3kdIr4rJY1Qr7VFlm","news_summary":"Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"BLVyZogeZffsYx36IM8zHdcz0QcmYTopr21SQ8kktmUvunlxkjOOdH","date":"Sep 16, 2023","link":"https://finance.yahoo.com/news/heres-why-were-not-too-132806718.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Cash Burn, Investment","company":"Alpha Tau Medical","layoffs":"Not mentioned","summary":"Alpha Tau Medical, a biotech company, is being analyzed for its cash burn rate. As of June 2023, the company had a cash reserve of US$94m and no debt, having burnt through US$19m in the last year. This gives it a cash runway of about 4.8 years. The companys cash burn has reduced by 20% year on year, suggesting it can continue operating for quite some time. Given the companys market capitalisation of US$230m, it could easily fund another years growth by issuing new shares or taking out a loan.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Cash Burn","Investment","Cash Runway","Share Dilution","Debt"],"date_of_event":"June 2023","valuation_amount":"US$230m","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"RoYgVtgm1XPUdLUcDI4nI99UhKauHWlUSLWS5AGKI8kJy4yx6cYEI4","news_summary":"Here's Why We're Not Too Worried About Alpha Tau Medical's (NASDAQ:DRTS) Cash Burn Situation","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"dDCELwwaB9I56M6OhNp9SR34EucBoTrlv1DLzoSoVMajv3zz1xUCsl","date":"Sep 14, 2023","link":"https://finance.yahoo.com/news/alpha-tau-treats-first-patient-123000460.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Cancer Treatment, Clinical Trial","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, announced the treatment of a patient with advanced inoperable pancreatic cancer in a clinical trial at Hadassah Medical Center in Jerusalem, Israel. The patient was treated with the companys innovative alpha-radiation cancer therapy, Alpha DaRT. The trial is designed for solid tumor patients who do not qualify for other existing trials or do not have other treatment options. The company is dedicated to improving the lives of cancer patients and believes that Alpha DaRT has the potential to transform the treatment landscape for malignant tumors worldwide.","partners":"Not mentioned","customers":"Hadassah Medical Center","investors":"Not mentioned","confidence":9,"key_topics":"Alpha DaRT, Pancreatic Cancer, Clinical Trial, Hadassah Medical Center, Israeli Technology","date_of_event":"Sept. 14, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Customers, Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"JtZod0AsCb6Hb68OiEW3k4aFV0T1JLOz39r9gSeeVU3pDM1KXGUanK","news_summary":"Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel’s Hadassah Medical Center","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"qLt2CgzoVTHFNgsS50ssFuApta9of3X2xA0zV6cDSG3CmVmhZQLhe9","date":"Aug 28, 2023","link":"https://finance.yahoo.com/news/alpha-tau-medical-announces-second-200200810.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Report, Clinical Trials","company":"Alpha Tau Medical Ltd.","layoffs":"N/A","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, reported its second quarter 2023 financial results and provided a corporate update. The company has treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada. Alpha Tau has also received a valuable land grant in Jerusalem to enable a standalone company headquarters and future increased manufacturing capacity. The company reported a cash, restricted cash, & deposits balance of $94.4 million with a runway for at least two years. The company is also advancing its ReSTART pivotal U.S. multi-center trial in recurrent cutaneous squamous cell carcinoma.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":10,"key_topics":["Clinical Trials","Financial Results","Expansion","Cancer Treatment","Investment"],"date_of_event":"Aug. 28, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"$94.4 million","structured_issues":["Investment","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Investment #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"n0vX1KceNYLC5BBFMR4AlKTFLUptmpYZWLwxdrf9Xw73RB1zkjvdpN","news_summary":"Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"HVMd8FrRrjYj2E5nteuACUqzsnICtJKIEE3GkWp9QAAAquy9mUmGXg","date":"Aug 24, 2023","link":"https://finance.yahoo.com/news/alpha-tau-medical-participate-september-120000233.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investor Conferences","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, announced that its management will participate in several investor conferences in September 2023. These include Citi’s 2023 Annual BioPharma Conference, the Emerging Growth Conference, and the Cantor Fitzgerald Global Healthcare Conference. Alpha Tau, founded in 2016, focuses on the research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Investor Conferences","Alpha DaRT","Cancer Therapy","Healthcare Conference","BioPharma Conference"],"date_of_event":"Aug. 24, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"3zvE5sQvFqgccJa2piG2HqxKzuP1ajp4zIkNct0CVOL653HFDA6utF","news_summary":"Alpha Tau Medical to Participate in September Investor Conferences","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"OcMpX33cHVFll8dSQjNhbly2Cdn4ffKM6WKXAEcH6ESZ2oGWSZThvl","date":"Aug 17, 2023","link":"https://finance.yahoo.com/news/alpha-tau-announces-robust-long-210000747.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Cancer Treatment, Clinical Trials","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd. announced initial long-term safety and tumor control outcomes for patients with unresectable, recurrent, or locally advanced head and neck or skin tumors treated with Alpha DaRT across four prospective trials. The trials, conducted between February 2017 and December 2022, showed an 89% complete response rate and a two-year local recurrence-free survival rate of 77%. The treatment also showed no grade 3 or higher acute treatment-related toxicities. The companys CEO, Uzi Sofer, expressed excitement over the results and the potential of Alpha DaRT for patients.","partners":"Not mentioned","customers":"Patients with unresectable, recurrent, or locally advanced head and neck or skin tumors","investors":"Not mentioned","confidence":9,"key_topics":["Cancer Therapy","Clinical Trials","Treatment Outcomes","Patient Safety","Future Studies"],"date_of_event":"Aug. 17, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"IRGUIEDG9UhT73kBk9T7ytcUoctReUOytb3A9glt5sTEOOiytF0s07","news_summary":"Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7DVgxAOU3zW9jmo4xfPfJmeHsOydzq2jDYgOX8QVDy5EESt4YL9yRI","date":"Aug 8, 2023","link":"https://finance.yahoo.com/news/presenting-emerging-growth-conference-august-110000739.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Conference, Growth Sectors","company":"EmergingGrowth.com","layoffs":"Not specified","summary":"EmergingGrowth.com, a leading independent small cap media portal, has announced the schedule for the 60th Emerging Growth Conference on August 9 and 10, 2023. The conference identifies companies across a variety of growth sectors that have strong management teams, innovative products and services, a focused strategy, and the potential for long-term growth. Companies presenting at the conference include Longeveron, ASP Isotopes, Alpha Tau Medical, Kintara Therapeutics, Sigyn Therapeutics, and many others.","partners":["Longeveron","ASP Isotopes","Alpha Tau Medical","Kintara Therapeutics","Sigyn Therapeutics","dynaCERT","Willow Biosciences","Intellabridge Technology Corporation","22nd Century Group","Jaguar Health","Regen BioPharma","Odyssey Health","Big Screen","Renforth Resources","ClearOne","Can-Fite BioPharma","Kodiak Copper Corp"],"customers":"Not specified","investors":"Not specified","confidence":9,"key_topics":["Emerging Growth Conference","Small Cap Media","Company Presentations","Investment Community","Growth Sectors"],"date_of_event":"August 9, 10, 2023","valuation_amount":"Not specified","impact_on_company":"Growth-Positive","investment_amount":"Not specified","structured_issues":"Partners","acquisition_amount":"Not specified","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"IwIsLuzITMom6az4IZLqvLPhEiEAIyvdHRKpbtBHZL8KhHYGNO8Jlu","news_summary":"Presenting on the Emerging Growth Conference on August 9 & 10 Register Now","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"x4OxfzoOwUmq4nJgpVsbpGYoBFyGAKJ6hfn2hdKTcAirNEVhDufbuM","date":"Aug 6, 2023","link":"https://finance.yahoo.com/news/insiders-own-24-alpha-tau-122852539.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investment, Ownership","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd. is primarily owned by individual investors, who hold 54% of the companys shares. Insiders, including CEO Uzi Sofer, hold 24% of the companys shares. Institutional investors have a small stake in the company, indicating that it is not particularly popular with professional investors at the moment. However, this could change if the company improves over time. Private companies hold 18% of the companys shares. The top 25 shareholders own less than half of the companys shares, indicating that the companys shares are widely disseminated and there is no dominant shareholder.","partners":"Not mentioned","customers":"Not mentioned","investors":["CEO Uzi Sofer"],"confidence":9,"key_topics":["Shareholder Groups","Institutional Ownership","Insider Ownership","Public Ownership","Private Company Ownership"],"date_of_event":"Not specified","valuation_amount":"US$268m","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xQGPVRdD5Rg0312lOxi3OtQPCWgXBN6f1m2QJwRVdowDBYMGCSjiTJ","news_summary":"Insiders own 24% of Alpha Tau Medical Ltd. (NASDAQ:DRTS) shares but individual investors control 54% of the company","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"i7L7QbeNJX0JUvfS01jJyOQLV9hTlhPpsW4ujpTDpkHLys6uHxheXX","date":"Aug 2, 2023","link":"https://finance.yahoo.com/news/alpha-tau-medical-present-emerging-130000559.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Conference Presentation","company":"Alpha Tau Medical Ltd.","layoffs":null,"summary":"Alpha Tau Medical Ltd., an Israeli medical device company, announced that its CFO, Raphi Levy, will present at the Emerging Growth Conference on August 9th, 2023. The company, which is known for its innovative alpha-radiation cancer therapy Alpha DaRT, invites attendees to register for the virtual conference. If attendees are unable to join the event live, an archived webcast will be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel.","partners":[],"customers":[],"investors":[],"confidence":9,"key_topics":["Emerging Growth Conference","Alpha DaRT","Cancer Therapy","Virtual Presentation","Investor Relations"],"date_of_event":"Aug. 02, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"poUzdhRDVvYap0VCi3yMJ4TDaClHmCHnyoD6feTO6ZNJvEXx8gYZxb","news_summary":"Alpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"i7jDEG6AG899NgLVAW0xTGyj3szx6aTceAaOnhG40ttwktwvUPdzu8","date":"Jun 13, 2023","link":"https://finance.yahoo.com/news/sidoti-events-llcs-virtual-june-120000431.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Expansion, Conferences","company":"Sidoti Events, LLC and Sidoti & Company, LLC","layoffs":"Not mentioned","summary":"Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has announced the schedule for its two-day June Small-Cap Conference taking place on June 14-15, 2023. Sidoti & Company formed Sidoti Events in 2023 to focus on its growing conference business and to better serve the needs of presenters and attendees. Sidoti Events hosts eight investor conferences each year, providing forums for interaction for small and microcap issuers and investors. The company benefits from Sidotis small- and microcap-focused nationwide sales force, which has relationships with approximately 500 institutional clients in North America.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Small-Cap Conference","Corporate Access","Investor Conferences","Company Sponsored Research","Institutional Clients"],"date_of_event":"June 13, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers","Partners","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers #Partners #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"O55CGFUUewBD38Kx3lBjGNwsio5FE6d2VkB3bKHj2VHSzzpzPmDvxZ","news_summary":"Sidoti Events, LLC's Virtual June Small-Cap Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"64j513vslppVW406gG5ppwuQ2UZJrccRipcZMWs5zzQNA15WuROOZS","date":"May 24, 2023","link":"https://finance.yahoo.com/news/alpha-tau-medical-participate-june-200100407.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investor Relations, Healthcare Conference","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, has announced that its management will participate in upcoming investor conferences. The company, known for developing the innovative alpha-radiation cancer therapy Alpha DaRT, will be present at the Jefferies Healthcare Conference in New York and the Citi European Healthcare Conference, which will be held virtually. Alpha DaRT is designed to enable potent alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":"Investor Conferences, Cancer Therapy, Alpha DaRT, Radium-224, Tumor Treatment","date_of_event":"May 24, 2023","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":"Management Changes","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"tK8V4rU4ps8gP8fK8tyjRah0pcZKO9x8R0m6BPdAi8x11HJI8zmufY","news_summary":"Alpha Tau Medical to Participate in June Investor Conferences","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"tuQjGdm3NONr78WEFeo4fHs0RxAT5xapXKoQ9R2QmfQb1q0inrtofP","date":"May 23, 2023","link":"https://finance.yahoo.com/news/alpha-tau-medical-announces-first-200100167.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Cancer Treatment, Clinical Trials","company":"Alpha Tau Medical Ltd.","layoffs":"N/A","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, has reported its Q1 2023 financial results and provided a corporate update. The company has initiated several clinical trials for its alpha-radiation cancer therapy, Alpha DaRT, in the US, Canada, and the UK. The trials are focused on various types of cancer, including skin, pancreatic, liver, and squamous cell carcinoma of the vulva. Alpha Tau has also received Health Canada approval to initiate a liver cancer feasibility trial. The company reported a net loss of $8.2 million for Q1 2023, compared to a net loss of $25.7 million in Q1 2022. As of March 31, 2023, the company had cash and cash equivalents of $100.5 million.","partners":"Jewish General Hospital in Montreal, Canada, Addenbrookes Hospital of the Cambridge University Hospitals NHS Foundation Trust","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Clinical Trials","Cancer Treatment","Financial Results","Regulatory Approval","Research and Development"],"date_of_event":"May 23, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Investment","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Investment #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"lfkMnZdHUBbxzSMzTr4I5x2pODPY4PVcw2YiFCHdVybJhUJZzCd6AH","news_summary":"Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ctJnuP5PBAOr6z3RcXJkZtqXsZuYk9jPjblqLTj3q2NuOTPEtDLMAY","date":"May 21, 2023","link":"https://nocamels.com/2023/05/new-cancer-radiation-therapy-kills-tumors-from-the-inside/","source":"nocamels.com","visible":1,"analysis":{"tags":"Cancer Treatment, Clinical Trials","company":"Alpha TAU","layoffs":"N/A","summary":"Jerusalem-based startup Alpha TAU is expanding its trials of a novel radiation treatment for cancer that targets tumors from the inside using alpha particles. The treatment, which is now in Phase 3 pivotal trials, has shown promising results in its pilot trial, with a 100% complete response rate in all 10 patients. The treatment uses a device to deliver alpha particles directly into the tumor, which has shown only mild or moderate side effects. The company is now preparing for the final trial before seeking FDA approval.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Radiation Therapy","FDA Approval","Clinical Trials","Cancer Treatment","Medical Innovation"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Expand","acquisition_amount":"N/A","structuredIssuesShow":"#Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"SvJgBihN5hgB5CtCBldLsOSUQ4jBK9u4pa4Gcx7GWr48yZFdTlJIWS","news_summary":"New Cancer Radiation Therapy Kills Tumors From The Inside","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"6VuXaZ0YSHqb6zy02reFl9v7kGFunbj4damoJOsGHtdMcTmda90e89","date":"May 17, 2023","link":"https://finance.yahoo.com/news/alpha-tau-expands-alpha-dart-203000056.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Medical Research, Cancer Treatment","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd. has announced the treatment of its first patient with squamous cell carcinoma of the vulva in a feasibility and safety study of Alpha DaRT at Addenbrookes Hospital of the Cambridge University Hospitals NHS Foundation Trust. The trial aims to recruit 10 participants with newly diagnosed or locally recurrent vulva cancer. The study will assess the safety and feasibility of using Alpha DaRT by measuring treatment-related adverse events in the 6-month follow-up period. The trial is part of Alpha Taus strategy to broaden the use of Alpha DaRT in other hard-to-treat indications such as cancers of the brain, pancreas, lung, and breast.","partners":"Addenbrookes Hospital of the Cambridge University Hospitals NHS Foundation Trust","customers":"Patients with squamous cell carcinoma of the vulva","investors":"Not mentioned","confidence":9,"key_topics":["Cancer Treatment","Clinical Trial","Alpha DaRT","Squamous Cell Carcinoma","Medical Research"],"date_of_event":"May 17, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Qy7ADg8OQKhzkkWcVErgDra5aues8WCUgbFwG4pctLfjSBH0DWgpEa","news_summary":"Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"hGNvi0GrRRptjtx0zsHSBAMrvJkBlzQEFOS3Km9hwn5tXXTBRUXrll","date":"May 11, 2023","link":"https://finance.yahoo.com/news/alpha-tau-announces-publication-us-200000684.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Cancer Treatment, Clinical Trials","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, has announced the successful results of its US multicenter pilot trial for the treatment of recurrent or unresectable skin cancer using its Alpha DaRT technology. The trial demonstrated a 100% Complete Response rate at 12 weeks post treatment with no device-related serious adverse events or systemic toxicity reported in the 10 patients treated. The company is now moving quickly to enroll eligible patients in its ongoing U.S. pivotal trial, Recurrent SCC Treatment with Alpha DaRT Radiation Therapy (ReSTART).","partners":"Memorial Sloan Kettering Cancer Center, University Cancer Centers, West Cancer Center","customers":"Patients with recurrent or unresectable skin cancer","investors":"Not mentioned","confidence":9,"key_topics":["Clinical Trial","Cancer Treatment","Alpha DaRT","Skin Cancer","Medical Research"],"date_of_event":"May 11, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"zVfq3fJkjeNiuboIPD2C2O9VH17nDWDqmnrlhBdsdO15BpaHkEsApc","news_summary":"Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"DtJXwqstYjVV2WgH4wKxIDuCmbhN1ChyMPaPoab3N2twMugDptDm0Y","date":"May 3, 2023","link":"https://finance.yahoo.com/news/alpha-tau-medical-present-guggenheim-200000270.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Management Participation","company":"Alpha Tau Medical Ltd.","layoffs":"Not Mentioned","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, announced that its CFO, Raphi Levy, will participate in a fireside chat at the Guggenheim Radiopharmaceuticals Day in New York City on May 15, 2023. Alpha Tau, known for its innovative alpha-radiation cancer therapy Alpha DaRT, also mentioned that Mr. Levy will be available for one-on-one investor meetings at the conference.","partners":"Not Mentioned","customers":"Not Mentioned","investors":"Not Mentioned","confidence":9,"key_topics":["Radiopharmaceuticals Day","Investor Meetings","Cancer Therapy","Alpha DaRT","Financial Officer"],"date_of_event":"May 15, 2023","valuation_amount":"Not Mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not Mentioned","structured_issues":"Investment","acquisition_amount":"Not Mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"TjPcHkpNZgn0POKVWNClBdKOjcyJ8qN8tzLvCAEqx6jpkRe7PVWDb3","news_summary":"Alpha Tau Medical to Present at Guggenheim Radiopharmaceuticals Day","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"zZcUkRHTsHKdgyHBW2qX94UYsVPvQuSUat5X7Q4UavrBQIecFDXfgd","date":"Apr 3, 2023","link":"https://finance.yahoo.com/news/alpha-tau-jgh-announce-alpha-131000328.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Clinical Trial, Cancer Treatment","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd. has announced the treatment of its first patient with advanced inoperable pancreatic cancer in a feasibility and safety study of Alpha DaRT at the Jewish General Hospital (JGH) in Montreal, Canada. The trial aims to recruit 30 participants with Stage II, III, or IV pancreatic cancer. The study will primarily examine the safety and feasibility of placing the Alpha DaRT sources in the tumor and the overall safety of the procedure. The trial is a cornerstone of Alpha Taus strategy to broaden the use of Alpha DaRT in other hard-to-treat indications.","partners":"Jewish General Hospital, McGill University, Faculty of Medicine","customers":"Patients with advanced inoperable pancreatic cancer","investors":"Not mentioned","confidence":9,"key_topics":["Clinical Trial","Cancer Treatment","Alpha DaRT","Pancreatic Cancer","Medical Innovation"],"date_of_event":"April 03, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers","Partners"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"wzVjCLlXmODyWCJZma8Q9BDYSu43HVE0JfDStvVrxaQjj5W5STQXTD","news_summary":"Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"F6zbmzyBUNnJy3g2En8EwSy85DxqOcu1floVkefWToMlFglhCanJOu","date":"Mar 29, 2023","link":"https://finance.yahoo.com/news/alpha-tau-medical-present-jefferies-200000253.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Presentation, Innovation Summit","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, has announced that its Chief Financial Officer, Raphi Levy, will present at the Jefferies Radiopharma Innovation Summit in New York City on April 3rd, 2023. The company, which focuses on the research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors, will also be available for one-on-one investor meetings at the conference.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":"Cancer Therapy, Alpha DaRT, Radiopharma Innovation Summit, Investor Meetings, Presentation","date_of_event":"April 3rd, 2023","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":"Management Changes","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"UjdhLTuKHucrhgyVL8NneYB1dHRbeH7Qd4lM9OtUVq4Yv5afpCrMPy","news_summary":"Alpha Tau Medical to Present at Jefferies Radiopharma Innovation Summit","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"s3j1VAJe9NRUlc1SBh5AjhBZiIWoVT8hHRHmH2t7dNFdj30X6VQTm8","date":"Mar 12, 2023","link":"https://finance.yahoo.com/news/alpha-tau-medical-confirms-no-123000721.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Medical Device, Cancer Therapy","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, has issued a statement in response to questions from investors and analysts regarding its relationship with Silicon Valley Bank (SVB). The company clarified that it maintains no accounts or other financial relationships with SVB and does not expect its closure to impact its operations. Alpha Tau, founded in 2016, focuses on the research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":"Alpha DaRT, Cancer Therapy, Financial Relationships, SVB, Investor Relations","date_of_event":"March 12, 2023","valuation_amount":"Not mentioned","impact_on_company":"Neutral","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"none;"},"sentiment":"Neutral","analysisId":"HKAEVbczfzmepQkuPP6pfYzJlX9reD7lGnBxRdvGRvH0RS2gk0lScM","news_summary":"Alpha Tau Medical Confirms No Direct Exposure to Silicon Valley Bank","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"DzISzixrOMBRuDGHS6U8znfh0f2zTnMnOKvI6XJHyHumm42mYksSpY","date":"Mar 9, 2023","link":"https://finance.yahoo.com/news/alpha-tau-medical-announces-full-211000540.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Healthcare, Cancer Treatment, Financial Results","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd. has reported its full year 2022 financial results and provided a corporate update. The company has initiated a U.S. pivotal trial in recurrent cutaneous squamous cell carcinoma and received Health Canada approval to initiate a liver cancer feasibility trial. It also raised $104 million in a combination with Healthcare Capital Corp. The company reported a net loss of $33.8 million for the year ended December 31, 2022, compared to a net loss of $27.3 million in 2021. As of December 31, 2022, the company had cash and cash equivalents, restricted cash and deposits amounting to $105.4 million.","partners":"Healthcare Capital Corp.","customers":"Not mentioned","investors":"Healthcare Capital Corp.","confidence":9,"key_topics":["Cancer Trials","Financial Results","Investment","Expansion","Regulatory Approval"],"date_of_event":"March 09, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$104 million","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HlapX4lJPfnZBJPcXY99XCYqujxzD6WtQTba7Ulb9i5sg5tHeWRoeF","news_summary":"Alpha Tau Medical Announces Full Year 2022 Financial Results and Provides Corporate Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"dULyhRe1fd87xIJp9aNTJQAXPudvkmTIcpf9JrgG7XRvS5jFWFz7tm","date":"Mar 8, 2023","link":"https://finance.yahoo.com/news/alpha-tau-announces-alpha-dart-220000525.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Cancer Treatment, Clinical Trial","company":"Alpha Tau Medical Ltd.","layoffs":"N/A","summary":"Alpha Tau Medical Ltd. has announced the enrollment and treatment of the first two patients in its ReSTART trial for the treatment of recurrent cutaneous squamous cell carcinoma (cSCC). The trial, which will enroll up to 86 patients in the U.S., Canada, Europe, and Israel, aims to assess the efficacy and safety of Alpha Taus intratumoral Alpha DaRT treatment. The companys CEO, Uzi Sofer, stated that this marks a significant milestone for the company and is a step towards gaining U.S. regulatory approval. The trials primary study endpoints include overall objective response rate, duration of response at 6-months from initial observation of a response to Alpha DaRT insertion, and safety of the Alpha DaRT treatment.","partners":"N/A","customers":["University Cancer Center in Houston, Texas"],"investors":"N/A","confidence":9,"key_topics":["ReSTART trial","cSCC treatment","Alpha DaRT","FDA approval","Patient enrollment"],"date_of_event":"March 08, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Fb12YO6t0rbQgGjGpGZwCtjP5G6bWkYIjf2LAXWUuD6uNu6848iNEY","news_summary":"Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"10WX1Wka9vDXGxXjeHfP8VruEglkLbJTnFVNDeJHxZOOHYkRFX19F4","date":"Mar 3, 2023","link":"https://finance.yahoo.com/news/alpha-tau-announces-grant-expanded-133000399.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Regulatory Approval, Cancer Therapy","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, has received an amended radioactive license from the Israeli Ministry of Environmental Protection. This license increases the maximum allowable amount of Thorium-228 for use and possession in its production facility in Jerusalem, which could support the production of up to 300,000 Alpha DaRT sources per year. The company has also received approvals to conduct pre-clinical experiments utilizing mice and rats at its Jerusalem headquarters. These developments will support the companys ongoing clinical trials and expansion of manufacturing capacity.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Radioactive License","Cancer Therapy","Clinical Trials","Manufacturing Capacity","Pre-clinical Laboratory"],"date_of_event":"March 03, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"CKzYKgkRmLUXV7hRfmazic38NmA04ug3TvrgFsKX1v5s8irAfNWsef","news_summary":"Alpha Tau Announces Grant of Expanded Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval at its Jerusalem Headquarters","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5x1GyobcdY1hTkaSutHorhD9DE0T8qm0TUD3GQppWPHU79eivsHFkP","date":"Mar 1, 2023","link":"https://finance.yahoo.com/news/alpha-tau-announces-health-canada-133000700.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Healthcare, Cancer Treatment","company":"Alpha Tau Medical Ltd.","layoffs":"N/A","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, has received authorization from Health Canada to conduct a feasibility and safety study of its alpha-radiation cancer therapy, Alpha DaRT, in the treatment of liver metastases. The study will be conducted at the McGill University Health Center in Montreal, Canada and aims to recruit 10 patients. The study will examine the feasibility and safety of delivering Alpha DaRT sources into the liver metastases and assess the frequency and severity of related adverse events. The authorization represents a significant milestone for the company.","partners":"Health Canada, McGill University Health Center","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Cancer Therapy","Health Canada Authorization","Feasibility Study","Liver Metastases Treatment","Clinical Trial"],"date_of_event":"March 01, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers","Partners"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"KVfmtE2Vwvgep4KayhVkNmfbs2oYl6Sxyxv6adJyhhNSXvvlyaAI9t","news_summary":"Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"s4NTtFZZ4t00S2UqGxkcBrF1oGhMS7imRWa6d24kPUix9w9w6eu9rL","date":"Feb 21, 2023","link":"https://finance.yahoo.com/news/alpha-tau-participate-citi-2023-210000585.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Healthcare, Medtech","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced its plans to participate in Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference on March 1, 2023. The conference will take place at Citi HQ Conference Center in New York City. Alpha Tau, an Israeli medical device company, focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors.","partners":"Citi","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":"Cancer Therapy, Conference Participation, Alpha DaRT, Healthcare Services, Medtech","date_of_event":"Feb. 21, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Partners","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"o4lussrKkSFPtJQUnWGFVRQ06q89ptfvHHKjyYNh3kXxO7VtxBWqwm","news_summary":"Alpha Tau to Participate in Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"pLoGplrDuTAZXDXPZVnaZy8OFFMdlPbpjevgr1Coe3fCYx34W5ScVM","date":"Dec 13, 2022","link":"https://finance.yahoo.com/news/alpha-tau-present-biotech-showcase-130000873.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Healthcare, Cancer Therapy","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., the developer of alpha-radiation cancer therapy Alpha DaRT, announced its plans to present at the Biotech Showcase and host institutional investor meetings. This event will take place in parallel with the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California. The companys CFO, Raphi Levy, will provide an overview of the company, its technology, recent pre-clinical and clinical progress, and upcoming clinical trials. The company was founded in 2016 and focuses on the research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors.","partners":"Not mentioned","customers":"Not mentioned","investors":"Institutional Investors","confidence":9,"key_topics":["Cancer Therapy","Investor Meetings","Biotech Showcase","Clinical Trials","Alpha DaRT Technology"],"date_of_event":"January 9-12, 2023","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"LM1dVQ3BHiYpeqTC2bgI1RCwCPp9zKPb0crbCuqti9VnNG3TB2E6de","news_summary":"Alpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event During J.P. Morgan Healthcare Conference in San Francisco in January 2023","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"6xhcfYvxKSKDggJrdWD3r7YE90D3v1coMQWhRvQd1VJeEYvm022MWz","date":"Nov 22, 2022","link":"https://finance.yahoo.com/news/alpha-tau-medical-announces-third-210200532.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Results, Management Changes, Clinical Trials","company":"Alpha Tau Medical Ltd.","layoffs":"N/A","summary":"Alpha Tau Medical Ltd. has reported its Q3 2022 financial results and provided a corporate update. The company has been preparing for a pivotal study in the US and exploring its Alpha DaRT oncology treatment platform. Peter Melnyk has been appointed as Chief Commercial Officer to focus on prelaunch activities across the US and international markets. The company has also initiated a number of feasibility trials and is developing new delivery technologies for Alpha DaRT. For Q3 2022, the company reported a net loss of $2.6 million. As of September 30, 2022, the company had cash and cash equivalents, restricted cash and short-term deposits amounting to $108.5 million.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Financial Results","Clinical Trials","Management Changes","Alpha DaRT Technology","Future Plans"],"date_of_event":"Nov. 22, 2022","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"mRN3WqY8NZqTHBttjmluTxVKwChEw6ztnSB4dt2dq9q0ZRJcxTmgbQ","news_summary":"Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"4MHPzRPzT9PcUI5R2ATuZP2Fwq197bNfhryrJAeYGmnFtNc5MDYOkC","date":"Nov 9, 2022","link":"https://finance.yahoo.com/news/alpha-tau-present-upcoming-november-130000455.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investor Conference","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, will be presenting at two investor conferences in November 2022. The company, known for its innovative alpha-radiation cancer therapy Alpha DaRT, will be present at the Jefferies London Healthcare Conference and the Piper Sandler 34th Annual Healthcare Conference. Alpha DaRT is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Investor Conference","Alpha DaRT","Cancer Therapy","Healthcare Conference","Medical Device"],"date_of_event":"Nov. 09, 2022","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"h044vkfvao1Jz3bOCRtAboQQkzj5bsaLYmBu9BiDgmJt8KUOyU3uZs","news_summary":"Alpha Tau to Present at Upcoming November Investor Conferences","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ghDhTdvRnVLlZ5pA1xxGQiOsYCsaMkLDjrD6lLKxGVctCnd10ylcyo","date":"Oct 21, 2022","link":"https://finance.yahoo.com/news/alpha-tau-announces-multiple-corporate-200100695.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Clinical Trials, Cancer Treatment","company":"Alpha Tau Medical Ltd.","layoffs":"N/A","summary":"Alpha Tau Medical Ltd. has received approval from the Medicines and Healthcare products Regulatory Agency of the UK to initiate a clinical trial for the treatment of primary and recurrent Squamous Cell Carcinoma of the vulva using Alpha DaRT. Health Canada has also approved the addition of Jewish General Hospital in Montreal as a second site in the companys clinical trial in advanced pancreatic cancer. The company will present results from its U.S. pilot feasibility study at the ASTRO 2022 Annual Meeting. The company is also working on a multi-center pivotal study for the treatment of recurrent cutaneous Squamous Cell Carcinoma using Alpha DaRT.","partners":"Addenbrooke’s Hospital, Jewish General Hospital, Centre Hospitalier de l’Université de Montréal, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center","customers":"Patients at Addenbrooke’s Hospital, Jewish General Hospital, Centre Hospitalier de l’Université de Montréal","investors":"N/A","confidence":9,"key_topics":["Clinical Trials","Cancer Treatment","Regulatory Approval","Research Presentation","Partnerships"],"date_of_event":"Oct. 21, 2022","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers","Partners"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"OzWEgfvzh6srYxZhWrOMnX2jIY0JLMEyAQhrcssnqpTvoxe5z1hk7W","news_summary":"Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"6S7nc4jhxJHUgtYuAllvFJi3M27nSVXQDoEQ7pzeari8FJsOloOhnV","date":"Sep 8, 2022","link":"https://finance.yahoo.com/news/alpha-tau-announces-acceptance-major-200500468.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Medical Research, Cancer Therapy","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd. has announced the acceptance of two pre-clinical studies in major peer-reviewed journals, demonstrating the significant potential synergies between Alpha DaRT therapy and standard-of-care solid tumor therapies. The studies, published in the International Journal of Radiation Oncology, Biology, Physics and Frontiers in Oncology, examine the transcriptional profile activated by Alpha DaRT and its potential to enhance responsiveness to immune checkpoint inhibition of the programmed cell death protein 1 (PD-1) blockade. The results demonstrate potential synergies with immune stimulation in mice and support the further exploration of the Alpha DaRT as a compelling local radiation therapy with the potential to induce antitumor immunity.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Cancer Therapy","Clinical Studies","Alpha DaRT","Immunotherapies","Chemotherapy"],"date_of_event":"Sept. 08, 2022","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"MOgknVQdLsX0GP1UPk0vTSKfv4GXvPiexqTTfTD6nb8KuzfaOGDUfL","news_summary":"Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demonstrating Significant Potential Synergies Between the Alpha DaRT Treatment and Standard-of-Care Immunotherapy, Chemotherapy and Anti-Angiogenic Therapy","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Yn23ZTIHkT88mAt1wotxLWqU1N8q5mGuYo79asGEcYoeVd3oe6MBLy","date":"Sep 1, 2022","link":"https://finance.yahoo.com/news/alpha-tau-appoints-industry-veteran-201500932.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Management Changes","company":"Alpha Tau Medical Ltd.","layoffs":"N/A","summary":"Alpha Tau Medical Ltd. has announced that Peter Melnyk, a member of its board of directors, has resigned from the board to assume the full-time position of Alpha Tau’s Chief Commercial Officer. Melnyk has previously served as CEO of Fortovia Therapeutics and Chief Commercial Officer of Novocure. He will now lead the commercialization efforts of Alpha Taus alpha-radiation cancer therapy, Alpha DaRT. The company is progressing towards securing further marketing approvals for Alpha DaRT and is expected to commence a U.S. pivotal multi-center study in recurrent squamous cell carcinoma.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Resignation","Appointment","Cancer Therapy","Alpha DaRT","Commercialization"],"date_of_event":"Sept. 01, 2022","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"5G7qEyl0Xq2IrZbYOfuPi3deovRgadf4la22v9QIjCFKj7YTQp08o4","news_summary":"Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"bd70eeee-1aa6-4ee7-9d24-45c63da61453","date":"Jun 30, 2022","link":"https://www.globes.co.il/news/article.aspx?_atscid=7_134353_204082920_2227311_0_Txtetaxjxdshwhus8sp&did=1001416653","source":"www.globes.co.il","visible":1,"analysis":{"tags":"SPAC, Cancer Treatment","company":"אלפא תאו (Alpha Tau)","layoffs":"N/A","summary":"Israeli company Alpha Tau, which develops innovative cancer treatments, merged with SPAC company Healthcare Capital Corp at a valuation of nearly $1 billion. However, the companys stock value has since dropped by almost 37% since the merger was completed in early March. Alpha Tau is now preparing to enter a multi-center clinical trial for its head, neck, and skin cancer product, and is also entering a first trial for pancreatic cancer. The company has raised approximately $70 million prior to the SPAC merger, and during the merger, it raised about $104 million.","partners":"Healthcare Capital Corp","customers":"N/A","investors":["Ourcrowd","Madison Ventures","Regah Ventures","Ronald Cohen","Alan Patrickov","Fidelity (FMR)","Barclays"],"confidence":9,"key_topics":["SPAC Merger","Cancer Treatment","Clinical Trials","Stock Value","Investment"],"date_of_event":"2022","valuation_amount":"$1 billion","impact_on_company":"growth-negative","investment_amount":"$104 million","structured_issues":["Public Trading","Investment"],"acquisition_amount":"N/A","structuredIssuesShow":"#Public Trading #Investment","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"VCFaEiH4mz9V5idyjlYfOOlJnQWqyyhURnJncSELKsxwIVxRntR74t","news_summary":"אלפא תאו הישראלית מפתחת טיפול חדשני לסרטן. האם היא תצליח?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"01db2a2a-8f0c-4118-b590-ad0521ddbbec","date":"Jun 22, 2022","link":"https://www.prnewswire.com/news-releases/alpha-tau-announces-treatment-of-first-prostate-cancer-patient-with-alpha-dart-301573470.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Cancer Therapy, Clinical Trials","company":"Alpha Tau Medical Ltd.","layoffs":"N/A","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, has announced the treatment of its first patient in a feasibility study evaluating the Alpha DaRT as a neoadjuvant therapy in patients with prostate cancer. The study aims to assess the feasibility and safety of intratumoral Alpha DaRT source implantation for the treatment of local prostate cancer prior to surgery. The study can recruit up to 10 patients and involves two separate procedures. The surgical resection will be performed at the Carmel Medical Center in Haifa, Israel.","partners":"Rambam Health Care Center, Carmel Medical Center","customers":"Patients with prostate cancer","investors":"N/A","confidence":8,"key_topics":"Prostate Cancer, Alpha DaRT, Clinical Study, Cancer Treatment, Medical Research","date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Customers, Expand","acquisition_amount":"N/A","structuredIssuesShow":"#Customers, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xUsr1eEBxdr5P9AAfLOx1ec8zMv4RMwjBrAIecaLSj7jc7uBYs8Luh","news_summary":"Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT™","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7ddfde1c-6a0e-41ef-a45b-e7207ebf55a4","date":"Jun 16, 2022","link":"https://www.prnewswire.com/il/news-releases/alpha-tau-announces-receipt-of-radioactive-license-to-allow-production-in-main-manufacturing-floor-at-its-jerusalem-site-amended-radioactive-license-with-increased-capacity-at-lawrence-ma-site-301569899.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Production Expansion, Licensing","company":"Alpha Tau Medical Ltd.","layoffs":"N/A","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, has announced that it has been granted an active radioactive license by the Israeli Ministry of Environmental Protection. This license allows the company to use and possess Thorium-228 and Radium-224, radioactive materials used in the production of the Alpha DaRT sources, in its production facility in Jerusalem. The license will enable the company to increase its production capacity by nearly three times. The company also announced that the Radiation Control Program of the Department of Public Health of the Commonwealth of Massachusetts has tripled the amount of Thorium-228 for use and possession at the Lawrence, MA site.","partners":"Israeli Ministry of Environmental Protection, Department of Public Health of the Commonwealth of Massachusetts","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Radioactive License","Production Capacity","Cancer Therapy","Global Manufacturing","Clinical Trials"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"FhE9Ld2q0kJZ1HQXyCiERaEAXKP8NBprKn4VgytlHuDZdBHoToQ77L","news_summary":"Alpha Tau Announces Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site, Amended Radioactive License with Increased Capacity at Lawrence, MA Site","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d4c329c6-1a28-4bec-8beb-e96ec4a036a5","date":"Jun 8, 2022","link":"https://www.prnewswire.com/news-releases/alpha-tau-announces-fda-approval-of-ide-to-initiate-multi-center-pivotal-study-of-alpha-dart-in-recurrent-cutaneous-scc-301564017.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"FDA Approval, Clinical Study","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, has received conditional approval from the U.S. Food and Drug Administration (FDA) for its Investigational Device Exemption (IDE) application. This approval allows Alpha Tau to initiate its multi-center pivotal study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (SCC) using its innovative alpha-radiation cancer therapy, Alpha DaRT. The clinical study will enroll up to 86 U.S. patients at up to 20 institutions in the U.S., and will focus on patients with recurrent cutaneous SCC who have failed at least first line standard of care therapy.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":["FDA Approval","Clinical Study","Cancer Therapy","Alpha DaRT","Investigational Device Exemption"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"zFXiP7xIkHVyeWIU5Ea2Epa9gU9RppbKDZ0wo3agQTJ9P9MGJYhiH8","news_summary":"Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d859b520-d0f1-46a6-9ada-ba5b13d15ce2","date":"Mar 21, 2022","link":"https://www.prnewswire.com/il/news-releases/alpha-tau-medical-ltd-appoints-ruth-alon-to-its-board-of-directors-301506826.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Management Changes, Healthcare","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, has announced the appointment of Ruth (Ruti) Alon to its Board of Directors. Ruti Alon is the founder and CEO of Medstrada and has extensive experience in advising healthcare companies. The company believes that her knowledge and experience will be a significant asset as they continue to grow. Alpha Tau Medical is known for its innovative alpha-radiation cancer therapy, Alpha DaRT.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Board Appointment","Cancer Therapy","Alpha DaRT","Healthcare","Medical Devices"],"date_of_event":"March 21, 2022","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":["Management Changes"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"01Y7OQWWsm4LRVD7udAmXAHP0xc19xhVbOI9cHcgY2ruSrxy0djBER","news_summary":"Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"4fb7b82b-8855-406a-8b0b-a9ed51a04eda","date":"Mar 7, 2022","link":"https://www.prnewswire.com/news-releases/alpha-tau-medical-and-healthcare-capital-corp-announce-completion-of-business-combination-301496675.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Merger, Public Trading","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and Healthcare Capital Corp., a special purpose acquisition company, announced the successful closing of their business combination. The combined company will continue to be led by Alpha Taus existing management team and its shares and warrants are expected to begin trading on Nasdaq under the ticker symbols DRTS and DRTSW. The merger has raised approximately $90 million in gross cash proceeds for Alpha Tau.","partners":"Healthcare Capital Corp.","customers":"Not mentioned","investors":"Healthcare Capital Corp.","confidence":9,"key_topics":["Merger","Public Trading","Investment","Cancer Therapy","Nasdaq"],"date_of_event":"March 7, 2022","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$90 million","structured_issues":["Public Trading","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Public Trading #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"viRO4krGhHVYoepd6KkoIZ7LImLKt0Lz4MCN87y5uG9ktU45Ncpmvk","news_summary":"Alpha Tau Medical and Healthcare Capital Corp. Announce Completion of Business Combination","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"a2c0841b-6207-469f-9a79-06ea92595d4a","date":"Jan 10, 2022","link":"https://en.globes.co.il/en/article-alpha-tau-reports-positive-skin-cancer-treatment-trial-1001398043","source":"en.globes.co.il","visible":1,"analysis":{"tags":"Clinical Trials, Cancer Therapy","company":"Alpha Tau Medical","layoffs":"None","summary":"Alpha Tau Medical, an Israeli alpha-radiation cancer therapy developer, has reported positive clinical trial results for its treatment for malignant skin and soft tissue cancers. All 10 patients in the trial reached the secondary endpoint for measurement of tumor response to its alpha-radiation cancer therapy Alpha DaRT. The company is preparing for a US multi-center clinical trial with the FDA this year. Alpha Tau Medical is also set to complete its SPAC merger with Healthcare Capital Corp. at a company valuation of $1 billion.","partners":"Healthcare Capital Corp.","customers":"Patients with malignant skin and soft tissue cancers","investors":"Healthcare Capital Corp.","confidence":9,"key_topics":["Clinical Trial Results","Cancer Treatment","SPAC Merger","Company Expansion","FDA Approval"],"date_of_event":"January 10, 2022","valuation_amount":"$1 billion","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers","Partners","Public Trading"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers #Partners #Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"kMMU1Asf3lEiJTyNbeK2joKfPG2rOnwoDUgTEBrvTitejWURFgkmNB","news_summary":"Alpha Tau reports positive skin cancer treatment trial","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"755f3763-9ff7-4f40-9c5a-71bea04a2b10","date":"Jan 10, 2022","link":"https://www.prnewswire.com/news-releases/alpha-tau-announces-results-of-first-us-clinical-trial-of-alpha-dart-in-malignant-skin--soft-tissue-cancers-showing-complete-response-in-all-ten-treated-tumors-at-approximately-12-weeks-and-no-product-related-serious-adverse-ev-301456989.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Clinical Trials, Cancer Therapy","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd., an Israeli medical device company, announced that all ten patients in its US multi-center pilot trial of the Alpha DaRT for malignant skin & soft tissue cancers have reached the secondary endpoint for measurement of tumor response. The study met its primary feasibility endpoint, as all patients had successful delivery of radiation by Alpha DaRT. The company is planning for a U.S. multi-center pivotal trial for skin cancer in 2022. Alpha Tau also announced a merger agreement with Healthcare Capital Corp. (HCCC), a special purpose acquisition company, to become a Nasdaq-listed public company.","partners":"Healthcare Capital Corp.","customers":"Patients in the US multi-center pilot trial","investors":"Healthcare Capital Corp.","confidence":9,"key_topics":["Alpha DaRT","Cancer Therapy","Clinical Trials","US Market","Merger Agreement"],"date_of_event":"Jan. 10, 2022","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers","Public Trading"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers #Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"wzYxSZcClQ6SVpBNTivMAqGjphc5UXssWEylB74mW5GkTFdny0xCHu","news_summary":"Alpha Tau Announces Results of First US Clinical Trial of Alpha DaRT™ in Malignant Skin & Soft Tissue Cancers, Showing Complete Response in All Ten Treated Tumors at Approximately 12 Weeks and No Product-Related Serious Adverse Events","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b185acfe-b32f-4631-8337-034399a3520a","date":"Oct 11, 2021","link":"https://en.globes.co.il/en/article-alpha-tau-receives-fda-nod-for-brain-tumor-device-1001386830","source":"en.globes.co.il","visible":1,"analysis":{"tags":"FDA Approval, SPAC Merger","company":"Alpha Tau Medical","layoffs":"N/A","summary":"Alpha Tau Medical, an Israeli alpha-radiation cancer therapy developer, has received its second Breakthrough Device Designation from the US Food and Drug Administration (FDA) for its Alpha DaRT treatment for patients with recurrent glioblastoma multiform (GBM). GBM is an aggressive malignant brain tumor with a less than 10% 5-year survival rate. Alpha Tau CEO Uzi Sofer expressed his excitement over the designation and the potential it brings for new solutions for GBM patients. In July, Alpha Tau agreed to a SPAC merger with Healthcare Capital Corp., which will see it listed on Wall Street by the end of the year at a valuation of nearly $1 billion.","partners":"Healthcare Capital Corp.","customers":"N/A","investors":"Healthcare Capital Corp.","confidence":"10","key_topics":["FDA Breakthrough Device Designation","Glioblastoma Multiform Treatment","SPAC Merger","Company Valuation","Investment"],"date_of_event":"October 11, 2021","valuation_amount":"$1 billion","impact_on_company":"growth-positive","investment_amount":"$275 million","structured_issues":["Investment","Public Trading"],"acquisition_amount":"N/A","structuredIssuesShow":"#Investment #Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"3eOKEMkj79CrU7YjQp7gH4kEksy53bj62h9TJC5IrmBabZQ95TxCzp","news_summary":"Alpha Tau receives FDA nod for brain tumor device","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"af1b1faf-a5b7-4585-8cb6-175088c6800f","date":"Jul 8, 2021","link":"https://en.globes.co.il/en/article-alpha-tau-plans-spac-merger-at-1b-valuation-1001377507","source":"en.globes.co.il","visible":1,"analysis":{"tags":"Merger, Cancer Therapy","company":"Alpha Tau Medical","layoffs":"Not mentioned","summary":"Alpha Tau Medical, an Israeli company developing alpha-radiation cancer therapy, has announced a merger with Nasdaq listed SPAC Healthcare Capital Corp. The merger will give Alpha Tau a valuation of $1 billion. Alpha Taus technology, Alpha DaRT, enables potent alpha-irradiation of solid tumors. The company has reported positive Phase I results for a clinical trial on patients with brain and neck tumors and squamous cell carcinoma skin cancer. Alpha Tau has raised $80 million to date.","partners":"Healthcare Capital Corp","customers":"Not mentioned","investors":["Shavit Capital","OurCrowd","Sir Ronald Cohen","Alan Patricof","Dynamic Loop Capital","Howard Sterling","Medison Ventures"],"confidence":9,"key_topics":["Merger","Cancer Therapy","Clinical Trials","Alpha DaRT Technology","Investment"],"date_of_event":"July 8, 2021","valuation_amount":"$1 billion","impact_on_company":"growth-positive","investment_amount":"$80 million","structured_issues":["Acquired-by","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Acquired-by #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cnlP4CMJeZkv5d7wOEAdgwLGuRbpARwIl6znA1K39wRObrbCow40ZU","news_summary":"Alpha Tau Medical agrees SPAC merger at $1b valuation","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"f86bc3fd-79df-4cab-bda5-b598dd0a8cf5","date":"Mar 17, 2021","link":"https://www.themarker.com/markets/.premium-1.9625215","source":"www.themarker.com","visible":1,"analysis":{"tags":"SPAC","company":"Alpha Tau Medical","layoffs":null,"summary":"Alpha Tau Medical, an Israeli company developing radiological treatments for cancer, is in talks to merge with a SPAC to go public on NASDAQ. The company has raised $80 million so far and could be valued at $1 billion post-merger. This move could make Alpha Tau one of the first pharma companies to join the SPAC trend. The merger would involve a company that has raised capital specifically to acquire a private company within a set timeframe.","partners":[],"customers":[],"investors":[],"confidence":10,"key_topics":["SPAC","Cancer","Radiology","Merger","NASDAQ"],"date_of_event":"March 17, 2021","valuation_amount":"$1 billion","impact_on_company":"growth-positive","investment_amount":"$80 million","structured_issues":["Public Trading","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"mD0tGNOoSACETao6eO6ICMd8wfhmpZQW1ZbXprtHscxcnU9cXzJ7C6","news_summary":"שיגעון הספאק: החברה הישראלית שנלחמת בסרטן בדרך לנאסד\"ק - לפי שווי של מיליארד ד","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"1ea347fd-24f3-4f28-968c-ab20fcd3a426","date":"Jan 12, 2021","link":"https://www.prnewswire.com/news-releases/alpha-tau-medical-announces-appointment-of-peter-melnyk-as-new-board-member-301206410.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Management Changes","company":"Alpha Tau Medical","layoffs":"Not mentioned","summary":"Alpha Tau Medical, an Israeli medical device company, has announced the appointment of Peter Melnyk to its Board of Directors. Melnyk is the CEO of Fortovia Therapeutics, a private equity-owned pharmaceutical company focused on oncology supportive care products. He has held leading roles in sales, marketing, and business development in top oncology franchises in the pharmaceutical and medical device industry. Alpha Tau Medical is currently conducting clinical trials in multiple clinical indications across the world, including its first US trial at Memorial Sloan Kettering Cancer Center in New York.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Board Appointment","Cancer Treatment"],"date_of_event":"Jan. 12, 2021","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Management Changes"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"h7ncgQYhX32YXCjeoZp3bBIbBIKCEys0Yq5M8ElfwEZzC6M2MVw97j","news_summary":"Alpha Tau Medical Announces Appointment of Peter Melnyk as New Board Member","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"18586e77-68f8-41e9-bf98-09d9745decaa","date":"Jun 4, 2020","link":"https://en.globes.co.il/en/article-israeli-cancer-therapy-co-alpha-tau-raises-26m-1001331322","source":"en.globes.co.il","visible":1,"analysis":{"tags":"Investment, Expansion","company":"Alpha Tau Medical","layoffs":"Not mentioned","summary":"Alpha Tau Medical, an Israeli company developing alpha-radiation cancer therapy, has closed a $26 million Series B financing round. Investors included Shavit Capital, Medison Ventures, and OurCrowd, along with private and family office investors from Israel and North America. The company has completed its first-in-human clinical trial of Alpha DaRT with squamous cell carcinoma patients from Italy and Israel. It is now conducting clinical trials worldwide, including its first US trial at Memorial Sloan Kettering Cancer Center in New York.","partners":"Memorial Sloan Kettering Cancer Center, CHUM","customers":"Not mentioned","investors":["Shavit Capital","Medison Ventures","OurCrowd"],"confidence":9,"key_topics":["Cancer Therapy","Series B Financing"],"date_of_event":"June 4, 2020","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$26 million","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"rTMSNrtxMGOfp9XKdnbARtYXadurF5ZknzB7kCBGPv3finRLJhcBwn","news_summary":"Israeli cancer therapy co Alpha Tau raises $26m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"359367e7-726f-4bda-ab71-75d3eb700fb1","date":"Apr 7, 2020","link":"https://www.prnewswire.com/news-releases/alpha-tau-medical-announces-exclusive-distribution-arrangement-with-medison-canada-for-breakthrough-cancer-treatment-alpha-dart-301036749.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Partnership, Distribution, Cancer Therapy","company":"Alpha Tau Medical","layoffs":"N/A","summary":"Alpha Tau Medical, an Israeli medical device company, and Medison Canada, a subsidiary of Medison Pharma, have entered into an exclusive distribution arrangement. Medison will have exclusive rights to commercialize and distribute Alpha Taus alpha-radiation cancer therapy, Alpha DaRT, in Canada for a 15-year period. The agreement includes a revenue split and Alpha Tau will receive upfront, regulatory and milestone sales-based fees of up to $9 million. Alpha Tau has also launched a clinical trial for patients with advanced pancreatic cancer in Montreal.","partners":"Medison Canada","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Distribution Arrangement","Cancer Therapy","Clinical Trials","Revenue Split","Market Expansion"],"date_of_event":"April 7, 2020","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Partners","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Partners #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"q2Audop8mLEZCdp8EU7oK90mshFFCwvT39cnfJYUNTVlXiOZShL1s1","news_summary":"Alpha Tau Medical Announces Exclusive Distribution Arrangement With Medison Canada for Breakthrough Cancer Treatment Alpha DaRT","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"38ef8d02-49d5-4b67-9179-a916f99d3568","date":"Feb 13, 2020","link":"https://www.jpost.com/HEALTH-SCIENCE/How-Israeli-technology-saved-78-years-old-Leah-from-skin-cancer-617514","source":"www.jpost.com","visible":1,"analysis":{"tags":"Biotech, Cancer Treatment, Virtual Reality, Ultrasound Therapy","company":"Alpha Tau Medical, Surgical Theater, Insightec","layoffs":"NA","summary":"The article highlights the innovative work of three Israeli biotech companies: Alpha Tau Medical, Surgical Theater, and Insightec. Alpha Tau Medical is developing a radiation therapy that attacks tumors while sparing healthy tissues. Surgical Theater offers a virtual reality platform that allows surgeons to simulate surgeries for training purposes. Insightecs technology treats conditions deep in the brain using ultrasound and magnetic-resonance imaging (MRI), thus avoiding invasive surgery. All three companies have had successful patient outcomes.","partners":"Lucile Packard Children’s Hospital, OurCrowd Global Investor Summit","customers":"Jonathan and Na’ama Ellman, Leah, Will Irwin","investors":"NA","confidence":10,"key_topics":"Cancer Treatment, Virtual Reality, Ultrasound Therapy, Israeli Biotech, Medical Innovation","date_of_event":"FEBRUARY 13, 2020","valuation_amount":"NA","impact_on_company":"growth-positive","investment_amount":"NA","structured_issues":"Customers, Partners","acquisition_amount":"NA","structuredIssuesShow":"#Customers, Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"6bEv1rlKoYEEQXEwiTOP803lzMD4xbUGrNJu6BZumh9rBCp0KuMwnD","news_summary":"https://www.jpost.com/HEALTH-SCIENCE/How-Israeli-technology-saved-78-years-old-Leah-from-skin-cancer-617514","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"70a6d5ac-dd78-4e26-913a-485cbc078d59","date":"Dec 27, 2019","link":"https://www.jpost.com/HEALTH-SCIENCE/Developing-first-alpha-particle-radiation-therapy-for-cancer-612236","source":"www.jpost.com","visible":1,"analysis":{"tags":"Cancer Treatment","company":"Alpha Tau Medical","layoffs":"Not mentioned","summary":"Alpha Tau Medical, an Israeli company, has developed a novel cancer treatment called Alpha DaRT, which destroys aggressive tumors while sparing healthy tissue. The treatment uses alpha radiation for the first time in solid tumor treatment. The company is currently in the clinical trial phase. The treatment has shown promising results, leading to tumor shrinkage in 100% of cases and total tumor destruction in over 78% of cases. Alpha Tau has grown rapidly, expanding from fewer than 10 employees in 2016 to more than 40 in 2020. The company is building global production facilities in Massachusetts, Israel, and Japan.","partners":["Memorial Sloan Kettering Cancer Center","Montreal University Hospital Center"],"customers":"Not mentioned","investors":["Shavit Capital","OurCrowd","Medison Ventures","Alan Patricof","Sir Ronald Cohen"],"confidence":9,"key_topics":["Cancer Treatment","Clinical Trials","Alpha DaRT","Investment","Expansion"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Lyhmuh36W7jtleYxC1Kk46me1kkORVoBT20MEUoS0VPyO7HsfZHwDm","news_summary":"https://www.jpost.com/HEALTH-SCIENCE/Developing-first-alpha-particle-radiation-therapy-for-cancer-612236","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"186439a5-dc93-4163-9bd8-6c5a4218fed4","date":"Dec 2, 2019","link":"https://en.globes.co.il/en/article-alpha-taus-new-cancer-radiology-method-proves-effective-1001309387","source":"en.globes.co.il","visible":1,"analysis":{"tags":"Cancer Treatment","company":"Alpha Tau Medical","layoffs":"Not mentioned","summary":"Alpha Tau Medical has reported positive results from its clinical trial for a new cancer treatment method based on Alpha Radiotherapy (Alpha DaRT). The method is designed to provide a more powerful and focused treatment. In the trial, Alpha Tau reported a response in 100% of tumors and a full response in 78% of tumors in patients with squamous cell carcinoma of the skin and of the head and neck. The company plans to continue testing the treatment on other types of cancer. Alpha Tau was restarted in 2016 and has since raised a total of $72 million.","partners":"Not mentioned","customers":"Not mentioned","investors":["Shavit Capital","OurCrowd","Madison Ventures","Sir Ronald Cohen","Alan Patricof"],"confidence":9,"key_topics":["Clinical Trial","Cancer Treatment","Investment","IPO","Alpha DaRT"],"date_of_event":"December 2, 2019","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$72 million","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"iHMOq65QLUZZT1ZzSkfqE3EiELIJ6yklf726T5OIn0oQ2ewRUp07au","news_summary":"Alpha Tau's new cancer radiology method proves effective","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"82519f11-22f5-42e9-9150-ff69c4e1a2b0","date":"Sep 27, 2019","link":"https://www.prnewswire.com/news-releases/alpha-tau-medical-appoints-professor-yona-keisari-as-chief-scientific-officer-300926575.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Management Changes, Research","company":"Alpha Tau Medical","layoffs":"NA","summary":"Alpha Tau Medical, a cancer biotech company, has announced the appointment of Prof. Yona Keisari as Chief Scientific Officer. Prof. Keisari, a leader in anti-tumoral immune biology and co-inventor of the Alpha DaRT, will lead the companys research activities towards curing cancer. Alpha DaRT is an alpha-radiation cancer therapy that has shown effectiveness in enhancing specific anti-tumor immune response. Alpha Tau Medical is currently running clinical trials globally in metastatic breast cancer as well as skin and head and neck cancer.","partners":["Memorial Sloan Kettering Cancer Center","Montreal University Hospital Center","IRST Meldola","Tokyo Medical and Dental University","National Cancer Center"],"customers":"NA","investors":"NA","confidence":10,"key_topics":["Cancer Treatment","Alpha DaRT","Management Appointment","Clinical Trials","Research"],"date_of_event":"Sept. 27, 2019","valuation_amount":"NA","impact_on_company":"growth-positive","investment_amount":"NA","structured_issues":["Management Changes"],"acquisition_amount":"NA","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"CKDjRSqPI0XB8AkAQuq9wOQuiRAoz9qWgJkQMuuKrjJhiQ65aM8nqO","news_summary":"Alpha Tau Medical Appoints Professor Yona Keisari as Chief Scientific Officer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"34543d21-1621-49f9-b6cf-97ac9dcc4e9e","date":"Apr 11, 2019","link":"https://www.biospace.com/article/releases/breakthrough-cancer-therapy-developer-alpha-tau-awarded-iso-13485-certificate-for-quality-management-of-medical-devices/?s=89","source":"www.biospace.com","visible":1,"analysis":{"tags":"Certification, Cancer Therapy","company":"Alpha Tau Medical","layoffs":"Not mentioned","summary":"Alpha Tau Medical, an Israeli biotech company, has been awarded ISO 13485:2016 certification for its alpha radiation cancer therapy, Alpha DaRT. The certification, awarded by the British Standards Institution, is an internationally-recognized quality standard for the design, development, production, installation and sale of medical devices. The certification will allow Alpha Tau to continue developing Alpha DaRT in compliance with the highest safety, efficacy and product performance standards. The company can now make its commercial product available for the first patient treatment, once the Alpha DaRT medical device regulatory file is approved.","partners":"British Standards Institution","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["ISO Certification","Cancer Therapy","Medical Devices","Quality Management","Commercialization"],"date_of_event":"April 11, 2019","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"JjujrNpBmk4zYwmYD2h29ZoaqCyY5sewvKCBC5oPPn0TUxTl3fBj7w","news_summary":"Breakthrough Cancer Therapy Developer, Alpha Tau, Awarded ISO 13485 Certificate for Quality Management of Medical Devices BioSpace","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"e437f90d-a89c-4f9c-88f2-dffa35287340","date":"Mar 26, 2019","link":"https://www.prnewswire.com/news-releases/cancer-biotech-firm-alpha-tau-medical-appoints-raphi-levy-of-goldman-sachs-as-chief-financial-officer-300818388.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Management Changes, Investment, Expand","company":"Alpha Tau Medical","layoffs":"Not mentioned","summary":"Alpha Tau Medical, an Israeli biotech company that focuses on R&D and commercialization of the first alpha-radiation based cancer treatment for solid tumors, has announced that Raphi Levy will join the company as Chief Financial Officer. Levy will focus on driving business growth, strategic private and public fundraising, advancing company strategy and expanding collaborations with leading enterprises worldwide. The company recently secured $29 million in private financing and is currently running three clinical studies in Israel and Italy.","partners":["Memorial Sloan Kettering","University of Montreal","Cambridge University Hospital"],"customers":"Not mentioned","investors":["Shavit Capital","Medison Ventures","OurCrowd"],"confidence":9,"key_topics":["Management Change","Investment","Expansion","Cancer Treatment","Clinical Trials"],"date_of_event":"March 26, 2019","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$29 million","structured_issues":["Management Changes","Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Management Changes #Investment #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"sMgJwYxRcpw4bnDgl6nlUVwWMHbplnh7NOWE5xoT3cBcF1SWIhYCi2","news_summary":"Cancer Biotech Firm Alpha Tau Medical Appoints Raphi Levy of Goldman Sachs as Chief Financial Officer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"6176a17d-21d4-49f8-9ad6-a161cd4215d8","date":"Jan 3, 2019","link":"https://www.israel21c.org/alpha-radiation-startup-eliminates-70-of-cancerous-tumors/","source":"www.israel21c.org","visible":1,"analysis":{"tags":"Medical Technology","company":"Alpha Tau","layoffs":"Not mentioned","summary":"Alpha Tau, an Israeli medical technology company, has developed a revolutionary cancer treatment using alpha radiation. The technology, which was patented by Tel Aviv University in 2003, was nearly lost due to disputes over intellectual property. However, Uzi Sofer, who previously served as CEO of Brainsway, formed Alpha Tau to further develop the technology. The company recently raised $29 million from Shavit Capital, Medison Ventures and OurCrowd. Alpha Tau is currently the only company to use alpha radiation to treat solid tumors. The company is planning further clinical trials for 2019.","partners":"Not mentioned","customers":"Not mentioned","investors":"Shavit Capital, Medison Ventures, OurCrowd","confidence":9,"key_topics":"Cancer Treatment, Alpha Radiation, Clinical Trials, Investment, Expansion","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$29 million","structured_issues":"Investment, Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Br9RPq6vSN8GP2tegCh2Y9wd8OIJXjWEGgFWgDLFNOmGIF0yWEcO8P","news_summary":"Alpha radiation startup eliminates 70% of cancerous tumors","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"703a5661-8641-4a7d-bd38-af66d29292d3","date":"Dec 17, 2018","link":"https://www.dailywire.com/news/39401/wow-israeli-company-reports-new-method-destroys-hank-berrien","source":"www.dailywire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"toZe87fi73OCKLwq7Qd6q5FS8uiJE6NBoGuLmtUOJMMyWitxQkHLLI","news_summary":"WOW: Israeli Company Reports New Method Destroys Cancerous Tumors","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"5ccf47fe-8999-4983-9f97-88fc6225151a","date":"Dec 12, 2018","link":"https://www.timesofisrael.com/anti-tumor-dart-could-point-the-way-to-new-arsenal-in-battle-against-cancer/?utm_source=Startup+Daily&utm_campaign=startup-daily-2018-12-12&utm_medium=email","source":"www.timesofisrael.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"5WpD0F4eZNinh0MYDcKcsXqa8X27jnpHyZwy8UM8rP1nyGhNBwjTma","news_summary":"Anti-tumor DaRT could point the way to new arsenal in battle against cancer","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"031eda4d-c0ef-465f-9183-0f54a59fd834","date":"Nov 9, 2018","link":"https://www.algemeiner.com/2018/11/09/israeli-startup-develops-breakthrough-in-radiation-cancer-therapy/","source":"www.algemeiner.com","visible":1,"analysis":{"tags":"Medical Technology, Cancer Therapy","company":"Alpha Tau Medical","layoffs":"Not mentioned","summary":"Israeli medical technology company, Alpha Tau Medical, has announced it will begin clinical trials of its breakthrough radiation cancer therapy, Alpha DaRT, with leading medical institutions in Italy. The company aims to receive approval from the European Commission by next year. The technology, which delivers high-precision alpha radiation to kill cancer cells while sparing healthy tissue, has shown promising results in pre-clinical trials. The clinical trials will take place at the Sapienza University of Rome and the IFO (Istituti Fisioterapici Ospitalieri).","partners":["Sapienza University of Rome","IFO (Istituti Fisioterapici Ospitalieri)"],"customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Clinical Trials","Cancer Therapy","Medical Technology","Radiation Therapy","European Approval"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Partners","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"uXNfGTUJnyeOWpTGFYOzPDsohJ6Zgm5HcoL4hvLIH73nsjgeQGiW7T","news_summary":"Israeli Startup Develops Breakthrough In Radiation Cancer Therapy","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"72715f32-58d2-4cd9-8f25-24784654fc61","date":"Sep 5, 2018","link":"https://en.globes.co.il/en/article-radiation-cancer-therapy-co-alpha-tau-medical-raises-29m-1001252691","source":"en.globes.co.il","visible":1,"analysis":{"tags":"Investment, Expansion","company":"Alpha Tau Medical","layoffs":"Not mentioned","summary":"Israeli cancer therapy developer Alpha Tau Medical has raised $29 million in a funding round led by Shavit Capital, with participation from OurCrowd, Medison Ventures and private equity investors Sir Ronald Cohen and Alan Patricof. The funds will be used to explore the potential of the companys Alpha DaRT cancer treatment in clinical trials worldwide and to establish global production facilities. Alpha Tau has already established subsidiaries in the US and Japan and is in the process of forming further collaborations.","partners":"Not mentioned","customers":"Not mentioned","investors":["Shavit Capital","OurCrowd","Medison Ventures","Sir Ronald Cohen","Alan Patricof"],"confidence":10,"key_topics":["Cancer Treatment","Financing Round","Clinical Trials","Alpha DaRT","Expansion"],"date_of_event":"September 5, 2018","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$29 million","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"nQbz4UZuGhjqEfu220QHoqyHQirQmGmmy9Sn572n4ebnPn3w5aM4vW","news_summary":"Radiation cancer therapy co Alpha Tau Medical raises $29m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5bc90b57-2db8-44fb-a8de-f5cc2f061b66","date":"Aug 22, 2018","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3744829,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"Investment, Expansion","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Israeli oncology company Alpha Tau Medical Ltd. is reportedly in the final stages of raising an investment of several tens of millions of dollars. The round is expected to close by the end of the month. The company, which uses alpha radiation to treat various types of solid tumors, has already raised $25 million to date. Alpha Taus technology has been approved by the Massachusetts Radiation Control Program, enabling it to initiate clinical trials in cancer centers across the U.S. The company is also in the process of establishing a U.S. production facility.","partners":"HekaBio K.K.","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Investment","Oncology","Radiation Therapy","Expansion","Partnership"],"date_of_event":"22.08.18","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Several tens of millions of dollars","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"oajidXECVqwQfOSZCfSVSRiU4Wk4RredHMRexxwcjI4EYtn3j8RGm2","news_summary":"Israeli Oncology Company Alpha Tau is Raising Funds","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"477b970a-7e20-42a3-9f11-25860c6f0e96","date":"Aug 21, 2018","link":"https://www.medicaldesignandoutsourcing.com/alpha-tau-wins-approval-to-test-cancer-targeting-device-in-the-u-s/","source":"www.medicaldesignandoutsourcing.com","visible":1,"analysis":{"tags":"Healthcare, Cancer Treatment","company":"Alpha Tau Medical","layoffs":"N/A","summary":"Alpha Tau Medical has received a Sealed Source and Device (SSD) approval from the Massachusetts Radiation Control Program, allowing it to begin U.S. clinical trials of its Alpha DaRT cancer treatment device. The device delivers high-precision alpha radiation to kill cancer cells while sparing healthy tissue. Preliminary results have shown the treatment to be safe and effective for treating squamous cell carcinoma tumors. The company is also establishing a new production facility in Lawrence, Massachusetts.","partners":"N/A","customers":"U.S. Hospitals","investors":"N/A","confidence":9,"key_topics":["Cancer Treatment","Clinical Trials","Radiation Therapy","SSD Approval","New Production Facility"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"GpWVOmIVjYlFmZ9O3Og9eHUuYO1AF6OEhA35ZjBVQALSceowscvPpL","news_summary":"Alpha Tau wins approval to test cancer-targeting device in the U.S. - Medical Design and Outsourcing","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"66bd7a13-26d2-4443-b74f-7869f6af8588","date":"Oct 30, 2017","link":"https://globenewswire.com/news-release/2017/10/30/1159841/0/en/Alpha-Tau-Medical-Initiates-First-Clinical-Trial-in-Italy-to-Treat-Cancer-with-Alpha-Radiation.html","source":"globenewswire.com","visible":1,"analysis":{"tags":"Clinical Trial, Cancer Treatment","company":"Alpha Tau Medical","layoffs":"Not mentioned","summary":"Israeli medical device company, Alpha Tau Medical, has announced its first clinical trial in Italy. The trial will evaluate the feasibility, safety, and efficacy of Alpha DaRT for the treatment of Squamous Cell Carcinoma (SCC) of the skin. The company hopes that the results from the study will reinforce the promising preliminary results of the ongoing SCC study at the Rabin Medical Center in Israel. Alpha Tau Medical is also finalizing protocols for various indications in collaboration with major cancer institutes around the world, including the United States, Germany, and France.","partners":"IRST, Meldola, Rabin Medical Center, Tel Aviv University","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":"Clinical Trial, Cancer Treatment, International Expansion, Alpha DaRT, Squamous Cell Carcinoma","date_of_event":"Oct. 30, 2017","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":"Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"R7gnDH3EDo84hvMBp8nIQ1KKgNDJmsURMvHRTqiwNAqpLaQi51YsDr","news_summary":"Alpha Tau Medical Initiates First Clinical Trial in Italy to Treat Cancer with Alpha Radiation","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"47310800-fa4e-4833-8a73-a51c28f5a715","date":"Jul 19, 2017","link":"http://www.prnewswire.com/news-releases/alpha-tau-medical-secures-second-funding-round-to-treat-solid-tumors-with-alpha-radiation-300490230.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Investment, Medical Research","company":"Alpha Tau Medical Ltd.","layoffs":"Not mentioned","summary":"Alpha Tau Medical Ltd. has raised 20% more capital than planned for its Alpha DaRT cancer treatment. The funding will be used to further develop the Alpha DaRT as a potent treatment for 11 different types of solid tumors. The preliminary results of its first clinical study showed that Alpha DaRT can effectively destroy solid tumors with no systemic adverse events. The company will soon start a similar study in Italy and is submitting research protocols for additional indications in Italy, Romania, France, and Germany. It is also seeking to initiate its first clinical study in the USA.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Cancer Treatment","Alpha DaRT","Clinical Study","Funding","Expansion"],"date_of_event":"July 18, 2017","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"z4eXENn4R84U0u6qNRSKwxE100AfaKq2af3wA5IKCbwiKn9ZEdyqx1","news_summary":"Alpha Tau Medical Secures Second Funding Round to Treat Solid Tumors With Alpha Radiation","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":120,"techcommunityinvolvement":null,"mediagallery":[{"id":"fadf2a1e-151f-46e6-b3d7-22082bcf2e7c","timestamp":"2021-02-17 12:37:00.000000","resources_type":2,"resources_title":"Alpha DaRT Cancer Treatment - Skin SCC Patient Testimonial","resources_file_name":"mYWpR0864zY","alt":"Alpha DaRT Cancer Treatment - Skin SCC Patient Testimonial logo","imageurl":"https://img.youtube.com/vi/mYWpR0864zY/0.jpg","url":"http://youtu.be/mYWpR0864zY"},{"id":"97beea39-e3b6-47fb-8156-e5a65f444c93","timestamp":"2019-10-31 15:09:24.000000","resources_type":2,"resources_title":"Alpha DaRT Brachytherapy - Clinical Experts' Testimonial","resources_file_name":"B5Wm1QL25K4","alt":"Alpha DaRT Brachytherapy - Clinical Experts' Testimonial logo","imageurl":"https://img.youtube.com/vi/B5Wm1QL25K4/0.jpg","url":"http://youtu.be/B5Wm1QL25K4"},{"id":"9dd20c4a-18e2-4719-b31b-19aaf61bd83c","timestamp":"2018-08-15 10:33:52.000000","resources_type":2,"resources_title":"Trailer","resources_file_name":"zJ4KWdKLA34","alt":"Trailer logo","imageurl":"https://img.youtube.com/vi/zJ4KWdKLA34/0.jpg","url":"http://youtu.be/zJ4KWdKLA34"},{"id":"ac8d5158-fc2c-4fec-9915-9049f4c82a6e","timestamp":"2018-01-14 10:12:34.000000","resources_type":2,"resources_title":"","resources_file_name":"ja2UQdFOueM","alt":"","imageurl":"https://img.youtube.com/vi/ja2UQdFOueM/0.jpg","url":"http://youtu.be/ja2UQdFOueM"}],"tags":["cancer","therapeutics","medical-technologies","oncology","healthcare-providers","hospitals","radiology","doctors","drug-delivery","therapeutic-devices","medical-devices","cancer-therapy","women-health","bioconvergence"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":[{"date":"2016-01-01","name":"Highly Potent and Conformal Alpha Emitters Radiotherapy for the Treatment of Solid Cancer Tumors","tags":["therapeutics","radiology","medical-technologies","oncology","treatments"],"category":"Medical Devices","tto_logo":"/image_cloud/ramot_tto_logo_f01045b8-6016-11e8-8e45-41fdcbb0dda7","university_logo":"/image_cloud/ramot_institution_logo_f01045b8-6016-11e8-8e45-41fdcbb0dda6"}],"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["Alpha DaRT"],"geomarkets":["Global"],"targetmarkets":[],"marketcapital":354204924,"marketcapitaldate":"2025-11-01T14:04:30.000Z","funding":{"investors":9,"lastfunding":"$36.9M","totalrounds":6,"fundingstage":"Public","totalfunding":"$181.9M","publicinvestors":9,"lastpublicfunding":36900000,"totalpublicrounds":6,"totalpublicfunding":181900000},"team":[{"name":"Uzi Sofer","email":"UziS@alphatau.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoIi7t9wIDA","bounced":false,"claimed":0,"founder":0,"urlname":"uzi-sofer","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgiJGB0QgM","position":"CEO & Chairman","last_name":"Sofer","claimtoken":"ynI442WIZfhNyvavsGcUNVNtN75I8LmpeAGt2T158Bwycc6l6DWyzz","first_name":"Uzi","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/uzi-sofer-b50b8518/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2024-10-22 18:03:15.000000","initials":"US","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Prof. Itzhak Kelson","email":"itzhak@alphataumedical.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoIjDkMcKDA","bounced":false,"claimed":0,"founder":1,"urlname":"prof-itzhak-kelson","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg8J-0nQsM","position":"Founder & Chief Physics Officer","last_name":"Kelson","claimtoken":"DpoB64FqGaEDnioEl9mctVQyUebehfWQiYrWCXKWgp62EXQ5zJDe6Z","first_name":"Prof. Itzhak","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2023-12-27 21:17:27.000000","initials":"PK","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Prof. Yona Keisari","email":"yona@alphataumedical.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwLKpi4oLDA","bounced":false,"claimed":0,"founder":1,"urlname":"prof-yona-keisari","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDA8uDdngoM","position":"Founder & Chief Scientific Officer","last_name":"Keisari","claimtoken":"pnJmWcVBXQa15144ygKo23ThWJYN0WZyZdMeQWmlPzFWuooOWY1PNz","first_name":"Prof. Yona ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/yona-keisari-7750221b1/","unsubscribed":false,"is_activeuser":0,"additionalemail":"yona.keisari@altheramedical.com","claimedemaildate":"2023-12-27 21:17:35.000000","initials":"PK","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Raphi Levy","email":"raphil@alphataumedical.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4OiepLcIDA","bounced":true,"claimed":0,"founder":0,"urlname":"raphi-levy","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgyMzupwgM","position":"CFO","last_name":"Levy","claimtoken":"ijdWPbfJl1hduL0PkFqwe0B2Y6aISoTGvNgQBk2aiuG2c7tUH88D9m","first_name":"Raphi","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/raphi-levy-8079256/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-12-27 21:17:37.000000","initials":"RL","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Robert Den","email":"RobertD@alphatau.com","phone":"","gender":"Male","userid":"0fyYeAWuN7rvKjoTv8b4R0QRla9g5APf7vH9ERP8s5YHwID3o59Tmb","bounced":false,"claimed":null,"founder":0,"urlname":"robert-den","visible":1,"memberid":"kb9BHWvDaATFITVkixzb4sFmAXMCkP7oUSwdUuLe9mWAjGhlr6CkZP","position":"CMO","last_name":"Den","claimtoken":"yXfJS3b5rggN6UEodyiOGd9Ivh6htHpJqAmWPT26LyX8tpqD8WzkPc","first_name":"Robert","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/robert-den-md-178680190/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2024-10-22 18:03:21.000000","initials":"RD","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Amnon Gat","email":"amnong@alphatau.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Ovt07AJDA","bounced":false,"claimed":0,"founder":0,"urlname":"amnon-gat","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgy---sAkM","position":"COO","last_name":"Gat","claimtoken":"v2r5VgxnvPF9TyjyDhqt4MPI9m4ppktsKt4QMQ6n1hsOsZkoIVdday","first_name":"Amnon","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/amnon-gat/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-12-27 21:17:40.000000","initials":"AG","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Ronen Segal","email":"ronens@alphatau.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4KvJgOAIDA","bounced":false,"claimed":0,"founder":0,"urlname":"ronen-segal-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg2-q52QsM","position":"CTO","last_name":"Segal","claimtoken":"VNZ1cCEsGZ0lMKW5fIplYyB6EMKf2YGmiVKjHG2YLOfyDyjZiV4SrB","first_name":"Ronen","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/ronen-segal-974a0094/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-12-27 21:17:44.000000","initials":"RS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Michael Tolub","email":"michael.tolub@gmail.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4NvJy_MIDA","bounced":false,"claimed":1,"founder":0,"urlname":"michael-tolub","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgq_vO2wkM","position":"Business Development Manager","last_name":"Tolub","claimtoken":"9f63d6e2ab8e41a1c7fea8572409007c82237c73cfb513c50cd94c83ec686f39","first_name":"Michael","picturekey":"$ahosPcY5Y6JlbQipiI71pWyKppQ6q9TQU5n696CJiV0zFZh3bP6BPx","claimeddate":"2021-02-17","linkedinurl":"https://www.linkedin.com/in/michael-tolub-67909717/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2021-02-17 14:42:01.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$ahosPcY5Y6JlbQipiI71pWyKppQ6q9TQU5n696CJiV0zFZh3bP6BPx","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwPi8kYoKDA","fullname":"Ayelet Beazley"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-06-04T00:00:00.000Z","crunchbaseid":"althera-medical-ltd","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Tamar Weiss","creator_email":"tamar.e.weiss@gmail.com","createdate":"2014-08-06T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":"Ayelet Beazley","affiliatedOrganizations":null,"timeline":[{"id":"kryRTuSPTfOqoEk11gaTCOQPbjQenE3fs8lnRKlTDERfujBjpmuNn6","date":"Apr 2025","amount":"$36.9M","source":"https://www.prnewswire.com/il/news-releases/oramed-pharmaceuticals-announces-36-9-million-investment-and-strategic-collaboration-with-alpha-tau-medical-302439636.html","eventtype":"FundingRoundEvent","investment":[{"name":"Oramed Pharmaceuticals","type":"Startup","amount":null,"hidden":false,"country":"Israel","fullurl":"/company_page/oramed-pharmaceuticals","logokey":"$DggyvZSXBAoXq5xJXQv1ThROXZqp3V4Q3VXwVPt64Rv5H9KHuHB76j","tagline":"Transforming Injectables into Oral Therapies","urlname":"/company_page/oramed-pharmaceuticals","isisraeli":null,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6qvK8JDA","fundingtype":"Startup","leadpartner":null,"investmentid":"wbH88j6r5yko9f8An45Loc4MsFo42tFN0S7FQIBxlf2L4bTDWzE9cH","fundingsubtype":"","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$DggyvZSXBAoXq5xJXQv1ThROXZqp3V4Q3VXwVPt64Rv5H9KHuHB76j","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":36900000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"gTIveuhM1pvtTnM1xHsUYoylItzStUQCLvGywRUzi984qzistjNpXQ","date":"Sep 2023","amount":"Undisclosed","source":"https://www.deepinsight.co.il/, http://pdf.secdatabase.com/44/0001213900-23-075741.pdf","eventtype":"FundingRoundEvent","investment":[{"name":"Deep Insight","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/deep-insight","logokey":"$6Kht3vvZTkEsRz2gHcIJPbJxeZ44TEHuR2TkDJZlvWavt59DmXo5II","tagline":null,"urlname":"/investor_page/deep-insight","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4PvwjMgLDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"A8KJjsTDb16bsGkZTwNuuPWtrSjHJLJ2EhNpooawrjvJbX5s5KYHHA","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$6Kht3vvZTkEsRz2gHcIJPbJxeZ44TEHuR2TkDJZlvWavt59DmXo5II","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJDM_dWkCww","date":"Mar 2022","amount":"Undisclosed","source":"https://www.alphatau.com/single-post/alpha-tau-medical-announces-full-year-2021-financial-results-and-provides-corporate-update","ticker":"DRTS","eventtype":"SpacEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$90M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","acquiredcompany_spac":"Healthcare Capital Corp","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","acquiredcompany_spac_id":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJDMiqnGCgw","acquiredcompany_spac_type":"Company","acquiredcompany_spac_hidden":true,"acquiredcompany_spac_fullurl":"/company_page/healthcare-capital-corp","acquiredcompany_spac_logokey":"$0QyTSA1xCTZxf3GYiM5Crm8JSoMMQqgFHjKODbsrMbsdnQ29MUKbsD","acquiredcompany_spac_urlname":"/company_page/healthcare-capital-corp","acquiredcompany_spac_homepage":null,"style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","acquiredcompany_spac_logourl":"https://storage.googleapis.com/clean-finder-353810/$0QyTSA1xCTZxf3GYiM5Crm8JSoMMQqgFHjKODbsrMbsdnQ29MUKbsD","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":90000000,"valuationnumber":0},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD-p_OLCgw","date":"Jun 2020","amount":"$26M","source":"https://en.globes.co.il/en/article-israeli-cancer-therapy-co-alpha-tau-raises-26m-1001331322, https://www.happinesscapital.com/portfolio?portfolio=alphatau","eventtype":"FundingRoundEvent","investment":[{"name":"Shavit Capital Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/shavit-capital-fund","logokey":"$vA62KRr8oAhlRh6QpynFhpg7usvk9m5bS7RnGX6t7fqsS2w1MGMsD9","tagline":null,"urlname":"/investor_page/shavit-capital-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNG_lJEKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"8ftSIkkvWYobxWMBXZVGpHfFpFZxFJS1ZSJ7jLfUdLxuS1FGyKF0Ul","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$vA62KRr8oAhlRh6QpynFhpg7usvk9m5bS7RnGX6t7fqsS2w1MGMsD9","leadcaption":"","followupcaption":"Follow on "},{"name":"Happiness Capital","type":"Investor","amount":null,"hidden":false,"country":"Hong Kong","fullurl":"/investor_page/happiness-capital","logokey":"$mMwKPhP09i59M1mi6aPfH4FNW0U64X4AWYiRiLUkVEX8VHqgXaEs3r","tagline":null,"urlname":"/investor_page/happiness-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4KuUi_IKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"EttjjWGr6CEPbglR750kyME8tjTUpNdU8iOAch9l6VF2Z4j99M216b","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$mMwKPhP09i59M1mi6aPfH4FNW0U64X4AWYiRiLUkVEX8VHqgXaEs3r","leadcaption":"","followupcaption":""},{"name":"Medison Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/medison-ventures","logokey":"$ZYQIPGOcp6Wh1zXUS1vkJmtjAHKgSf1LdooRROK80P0vfXhwwdT3En","tagline":null,"urlname":"/investor_page/medison-ventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4LT91I8KDA","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"X4Y3FkrKYVezKbpSfh7ARZdVThKY27rorGkMoySA8I1gdrBRLZUxmy","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZYQIPGOcp6Wh1zXUS1vkJmtjAHKgSf1LdooRROK80P0vfXhwwdT3En","leadcaption":"","followupcaption":"Follow on "},{"name":"OurCrowd","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/ourcrowd","logokey":"$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","tagline":null,"urlname":"/investor_page/ourcrowd","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7H-oQKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"dBTAdQas8HTqZdK6oCDRJtI4DHjfU04m1oWxgmr3oOOHFmRTGSfXwE","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":26000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCE7s_JCww","date":"Sep 2018","amount":"$29M","source":"Migrated + type of round was confirmed with their Marcom Manager + with their BD manager","eventtype":"FundingRoundEvent","investment":[{"name":"OurCrowd","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/ourcrowd","logokey":"$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","tagline":null,"urlname":"/investor_page/ourcrowd","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7H-oQKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"7c2522e2-3512-47c6-b5c0-1f2edaddcc87","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","leadcaption":"","followupcaption":""},{"name":"Sir Ronald Cohen","type":"Investor","amount":0,"hidden":false,"country":"United Kingdom","fullurl":"/investor_page/sir-ronald-cohen","logokey":"$iU9VgY90ilgzaZl3pQJZj7K6k9KXRv5CvaFM4zKXoywywRsDUEZlrx","tagline":"","urlname":"/investor_page/sir-ronald-cohen","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCkiZqXCQw","fundingtype":"Angel","leadpartner":null,"investmentid":"81904a9c-067c-4e98-a1b3-0a9e75f5dff8","fundingsubtype":"Angel","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$iU9VgY90ilgzaZl3pQJZj7K6k9KXRv5CvaFM4zKXoywywRsDUEZlrx","leadcaption":"","followupcaption":""},{"name":"Viking Macabee Ventures","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/viking-macabee-ventures","logokey":null,"tagline":"","urlname":"/investor_page/viking-macabee-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODxxIXJCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"8d6cfdaa-671c-4ad0-8d8f-b1e879f37843","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Private","leadpartnermemberid":null,"investmentVisibilityClassName":"private-visibility","investmentVisibilityTooltip":"tooltip tooltip-html-content='\n\n'","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Alan Patricof","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/alan-patricof","logokey":"$9BcJ96jbydjDE8Y1IWdeWslMNscbzYOab4Q5jZbXcRQgE8ErlrwqBT","tagline":"","urlname":"/investor_page/alan-patricof","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCkiczGCAw","fundingtype":"Angel","leadpartner":null,"investmentid":"c84e2d6e-0aa9-4669-bf12-1c7f31e1333f","fundingsubtype":"Angel","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$9BcJ96jbydjDE8Y1IWdeWslMNscbzYOab4Q5jZbXcRQgE8ErlrwqBT","leadcaption":"","followupcaption":""},{"name":"Medison Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/medison-ventures","logokey":"$ZYQIPGOcp6Wh1zXUS1vkJmtjAHKgSf1LdooRROK80P0vfXhwwdT3En","tagline":null,"urlname":"/investor_page/medison-ventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4LT91I8KDA","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"c891ce7a-25ab-42ea-a3e6-be1913b2c3dd","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZYQIPGOcp6Wh1zXUS1vkJmtjAHKgSf1LdooRROK80P0vfXhwwdT3En","leadcaption":"","followupcaption":""},{"name":"Shavit Capital Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/shavit-capital-fund","logokey":"$vA62KRr8oAhlRh6QpynFhpg7usvk9m5bS7RnGX6t7fqsS2w1MGMsD9","tagline":null,"urlname":"/investor_page/shavit-capital-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNG_lJEKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"d9b745ac-aaf9-4cc4-9af0-b6f96ea74331","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$vA62KRr8oAhlRh6QpynFhpg7usvk9m5bS7RnGX6t7fqsS2w1MGMsD9","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":29000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCk8PPKCgw","date":"Jul 2017","amount":"Undisclosed","source":"Migrated","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"1/2016","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Alpha Tau Medical","logourl":"https://storage.googleapis.com/clean-finder-353810/$netRzF6PJ9RqM0XYpCnTdyrbSmywONizZq2EzALdvgSgRXQEZGAOl1","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$netRzF6PJ9RqM0XYpCnTdyrbSmywONizZq2EzALdvgSgRXQEZGAOl1","seoabout":"Alpha Tau is a medical device company that focuses on the development and commercialization of its Diffusing Alpha-emitters Radiation Therapy (DaRT) for th...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":8,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Treatment & Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationDelimited":["TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA>Medical Treatment & Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA/Medical Treatment & Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Medical Devices","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices","children":[{"title":"Medical Treatment & Therapeutics","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices>Medical Treatment & Therapeutics"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Providers","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals"}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Treatment & Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Medical Devices","Medical Treatment & Therapeutics"],"coreTechnology":["Biologicals"],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Providers"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJDM_dWkCww","date":"Mar 2022","amount":"Undisclosed","source":"https://www.alphatau.com/single-post/alpha-tau-medical-announces-full-year-2021-financial-results-and-provides-corporate-update","ticker":"DRTS","eventtype":"SpacEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$90M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","acquiredcompany_spac":"Healthcare Capital Corp","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","acquiredcompany_spac_id":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJDMiqnGCgw","acquiredcompany_spac_type":"Company","acquiredcompany_spac_hidden":true,"acquiredcompany_spac_fullurl":"/company_page/healthcare-capital-corp","acquiredcompany_spac_logokey":"$0QyTSA1xCTZxf3GYiM5Crm8JSoMMQqgFHjKODbsrMbsdnQ29MUKbsD","acquiredcompany_spac_urlname":"/company_page/healthcare-capital-corp","acquiredcompany_spac_homepage":null,"style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","acquiredcompany_spac_logourl":"https://storage.googleapis.com/clean-finder-353810/$0QyTSA1xCTZxf3GYiM5Crm8JSoMMQqgFHjKODbsrMbsdnQ29MUKbsD","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":90000000,"valuationnumber":0}],"privateequityfunding":[{"id":"kryRTuSPTfOqoEk11gaTCOQPbjQenE3fs8lnRKlTDERfujBjpmuNn6","date":"Apr 2025","amount":"$36.9M","source":"https://www.prnewswire.com/il/news-releases/oramed-pharmaceuticals-announces-36-9-million-investment-and-strategic-collaboration-with-alpha-tau-medical-302439636.html","eventtype":"FundingRoundEvent","investment":[{"name":"Oramed Pharmaceuticals","type":"Startup","amount":null,"hidden":false,"country":"Israel","fullurl":"/company_page/oramed-pharmaceuticals","logokey":"$DggyvZSXBAoXq5xJXQv1ThROXZqp3V4Q3VXwVPt64Rv5H9KHuHB76j","tagline":"Transforming Injectables into Oral Therapies","urlname":"/company_page/oramed-pharmaceuticals","isisraeli":null,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6qvK8JDA","fundingtype":"Startup","leadpartner":null,"investmentid":"wbH88j6r5yko9f8An45Loc4MsFo42tFN0S7FQIBxlf2L4bTDWzE9cH","fundingsubtype":"","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$DggyvZSXBAoXq5xJXQv1ThROXZqp3V4Q3VXwVPt64Rv5H9KHuHB76j","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":36900000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"gTIveuhM1pvtTnM1xHsUYoylItzStUQCLvGywRUzi984qzistjNpXQ","date":"Sep 2023","amount":"Undisclosed","source":"https://www.deepinsight.co.il/, http://pdf.secdatabase.com/44/0001213900-23-075741.pdf","eventtype":"FundingRoundEvent","investment":[{"name":"Deep Insight","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/deep-insight","logokey":"$6Kht3vvZTkEsRz2gHcIJPbJxeZ44TEHuR2TkDJZlvWavt59DmXo5II","tagline":null,"urlname":"/investor_page/deep-insight","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4PvwjMgLDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"A8KJjsTDb16bsGkZTwNuuPWtrSjHJLJ2EhNpooawrjvJbX5s5KYHHA","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$6Kht3vvZTkEsRz2gHcIJPbJxeZ44TEHuR2TkDJZlvWavt59DmXo5II","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD-p_OLCgw","date":"Jun 2020","amount":"$26M","source":"https://en.globes.co.il/en/article-israeli-cancer-therapy-co-alpha-tau-raises-26m-1001331322, https://www.happinesscapital.com/portfolio?portfolio=alphatau","eventtype":"FundingRoundEvent","investment":[{"name":"Shavit Capital Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/shavit-capital-fund","logokey":"$vA62KRr8oAhlRh6QpynFhpg7usvk9m5bS7RnGX6t7fqsS2w1MGMsD9","tagline":null,"urlname":"/investor_page/shavit-capital-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNG_lJEKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"8ftSIkkvWYobxWMBXZVGpHfFpFZxFJS1ZSJ7jLfUdLxuS1FGyKF0Ul","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$vA62KRr8oAhlRh6QpynFhpg7usvk9m5bS7RnGX6t7fqsS2w1MGMsD9","leadcaption":"","followupcaption":"Follow on "},{"name":"Happiness Capital","type":"Investor","amount":null,"hidden":false,"country":"Hong Kong","fullurl":"/investor_page/happiness-capital","logokey":"$mMwKPhP09i59M1mi6aPfH4FNW0U64X4AWYiRiLUkVEX8VHqgXaEs3r","tagline":null,"urlname":"/investor_page/happiness-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4KuUi_IKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"EttjjWGr6CEPbglR750kyME8tjTUpNdU8iOAch9l6VF2Z4j99M216b","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$mMwKPhP09i59M1mi6aPfH4FNW0U64X4AWYiRiLUkVEX8VHqgXaEs3r","leadcaption":"","followupcaption":""},{"name":"Medison Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/medison-ventures","logokey":"$ZYQIPGOcp6Wh1zXUS1vkJmtjAHKgSf1LdooRROK80P0vfXhwwdT3En","tagline":null,"urlname":"/investor_page/medison-ventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4LT91I8KDA","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"X4Y3FkrKYVezKbpSfh7ARZdVThKY27rorGkMoySA8I1gdrBRLZUxmy","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZYQIPGOcp6Wh1zXUS1vkJmtjAHKgSf1LdooRROK80P0vfXhwwdT3En","leadcaption":"","followupcaption":"Follow on "},{"name":"OurCrowd","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/ourcrowd","logokey":"$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","tagline":null,"urlname":"/investor_page/ourcrowd","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7H-oQKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"dBTAdQas8HTqZdK6oCDRJtI4DHjfU04m1oWxgmr3oOOHFmRTGSfXwE","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":26000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCE7s_JCww","date":"Sep 2018","amount":"$29M","source":"Migrated + type of round was confirmed with their Marcom Manager + with their BD manager","eventtype":"FundingRoundEvent","investment":[{"name":"OurCrowd","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/ourcrowd","logokey":"$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","tagline":null,"urlname":"/investor_page/ourcrowd","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7H-oQKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"7c2522e2-3512-47c6-b5c0-1f2edaddcc87","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","leadcaption":"","followupcaption":""},{"name":"Sir Ronald Cohen","type":"Investor","amount":0,"hidden":false,"country":"United Kingdom","fullurl":"/investor_page/sir-ronald-cohen","logokey":"$iU9VgY90ilgzaZl3pQJZj7K6k9KXRv5CvaFM4zKXoywywRsDUEZlrx","tagline":"","urlname":"/investor_page/sir-ronald-cohen","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCkiZqXCQw","fundingtype":"Angel","leadpartner":null,"investmentid":"81904a9c-067c-4e98-a1b3-0a9e75f5dff8","fundingsubtype":"Angel","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$iU9VgY90ilgzaZl3pQJZj7K6k9KXRv5CvaFM4zKXoywywRsDUEZlrx","leadcaption":"","followupcaption":""},{"name":"Viking Macabee Ventures","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/viking-macabee-ventures","logokey":null,"tagline":"","urlname":"/investor_page/viking-macabee-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODxxIXJCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"8d6cfdaa-671c-4ad0-8d8f-b1e879f37843","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Private","leadpartnermemberid":null,"investmentVisibilityClassName":"private-visibility","investmentVisibilityTooltip":"tooltip tooltip-html-content='\n\n'","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Alan Patricof","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/alan-patricof","logokey":"$9BcJ96jbydjDE8Y1IWdeWslMNscbzYOab4Q5jZbXcRQgE8ErlrwqBT","tagline":"","urlname":"/investor_page/alan-patricof","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCkiczGCAw","fundingtype":"Angel","leadpartner":null,"investmentid":"c84e2d6e-0aa9-4669-bf12-1c7f31e1333f","fundingsubtype":"Angel","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$9BcJ96jbydjDE8Y1IWdeWslMNscbzYOab4Q5jZbXcRQgE8ErlrwqBT","leadcaption":"","followupcaption":""},{"name":"Medison Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/medison-ventures","logokey":"$ZYQIPGOcp6Wh1zXUS1vkJmtjAHKgSf1LdooRROK80P0vfXhwwdT3En","tagline":null,"urlname":"/investor_page/medison-ventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4LT91I8KDA","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"c891ce7a-25ab-42ea-a3e6-be1913b2c3dd","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZYQIPGOcp6Wh1zXUS1vkJmtjAHKgSf1LdooRROK80P0vfXhwwdT3En","leadcaption":"","followupcaption":""},{"name":"Shavit Capital Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/shavit-capital-fund","logokey":"$vA62KRr8oAhlRh6QpynFhpg7usvk9m5bS7RnGX6t7fqsS2w1MGMsD9","tagline":null,"urlname":"/investor_page/shavit-capital-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNG_lJEKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"d9b745ac-aaf9-4cc4-9af0-b6f96ea74331","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$vA62KRr8oAhlRh6QpynFhpg7usvk9m5bS7RnGX6t7fqsS2w1MGMsD9","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":29000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCk8PPKCgw","date":"Jul 2017","amount":"Undisclosed","source":"Migrated","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}![](\"/assets/private-visibility.svg\"/)
\n ![](\"/assets/internal-visibility.svg\"/)
\n